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The primary purpose of the National Antimicrobial Resistance Monitoring System (NARMS) at the Centers for 
Disease Control and Prevention (CDC) is to monitor antimicrobial resistance among enteric bacteria isolated from 
humans. Other components of the interagency NARMS program include surveillance for resistance in enteric 
bacteria isolated from foods, conducted by the U.S. Food and Drug Administration’s Center for Veterinary 
Medicine (FDA-CVM) 
(http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/NationalAntimicrobialResistanceMoni
toringSystem/default.htm), and for resistance in enteric bacteria isolated from animals, conducted by the U.S. 
Department of Agriculture’s Agricultural Research Service (USDA-ARS) 
(http://www.ars.usda.gov/Business/docs.htm?docid=6750&page=1).  
 
Many NARMS activities are conducted within the framework of two CDC programs: the Foodborne Diseases 
Active Surveillance Network (FoodNet), which is part of CDC’s Emerging Infections Program (EIP), and the 
Epidemiology and Laboratory Capacity (ELC) Program. In addition to population-wide surveillance of resistance in 
enteric pathogens, the NARMS program at CDC also conducts research into the mechanisms of resistance and 
performs susceptibility testing of isolates of pathogens that have caused outbreaks. 
 
Before NARMS was established, CDC monitored antimicrobial resistance in Salmonella, Shigella, and 
Campylobacter through periodic surveys of isolates from a panel of sentinel counties. NARMS at CDC began in 
1996 with ongoing monitoring of antimicrobial resistance among clinical isolates of non-Typhi Salmonella (refers 
to all serotypes other than Typhi, (which causes typhoid fever) and Escherichia coli O157 in 14 sites. In 1997, 
testing of clinical isolates of Campylobacter was initiated in the five sites then participating in FoodNet. Testing of 
clinical Salmonella ser. Typhi and Shigella isolates was added in 1999. Starting in 2003, all 50 states forwarded 
all Salmonella ser. Typhi isolates and a representative sample of non-Typhi Salmonella, Shigella, and E. coli 
O157 isolates to NARMS for antimicrobial susceptibility testing, and 10 states now participating in FoodNet have 
been conducting Campylobacter surveillance. Since 2008, all 50 states have also been forwarding every 
Salmonella ser. Paratyphi A and C to NARMS for antimicrobial susceptibility testing. Beginning in 2009, NARMS 
also performed susceptibility testing on isolates of Vibrio species other than V. cholerae. NARMS participating 
public health laboratories were asked to forward every isolate of Vibrio species other than V. cholerae that they 
received to CDC for antimicrobial susceptibility testing.  
 
This annual report includes CDC’s surveillance data for 2012 for non-typhoidal Salmonella (refers to serotypes 
not causing typhoid fever), typhoidal Salmonella (serotypes Typhi, Paratyphi A, Paratyphi B [tartrate negative], 
and Paratyphi C), Shigella, Campylobacter, E. coli O157, and Vibrio species other than V. cholerae. Surveillance 
data include the number of isolates of each pathogen tested by NARMS and the number and percentage of 
isolates that were resistant to each of the antimicrobial agents tested. Data for earlier years are presented in 
tables and graphs when appropriate. Antimicrobial classes defined by the Clinical and Laboratory Standards 
Institute (CLSI) are used in data presentation and analysis.   
 
This report uses the World Health Organization’s categorization of antimicrobials of critical importance to human 
medicine (Appendix A) in the tables that present minimum inhibitory concentrations (MIC) and resistant 
percentages.  
 
Additional NARMS data and more information about NARMS activities are available at http://www.cdc.gov/narms/. 







Epidemiological Cut-Off Values (ECOFFs) for the Interpretation of Campylobacter spp. Susceptibility Data 
 
In this report, NARMS used a different approach for interpreting antimicrobial susceptibility data for 
Campylobacter than it has used previously. In previous reports, NARMS used clinical interpretive criteria from the 
Clinical and Laboratory Standards Institute (CLSI) to define susceptible (S), intermediate (I) and resistant (R) 
categories. In this report, NARMS instead used epidemiological cut-off values (ECOFFs) provided by the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST). A more detailed description of ECOFFs 
can be found on page 17. 
 
  




Surveillance Population  
 
In 2012, all 50 states and the District of Columbia participated in NARMS, representing the entire U.S. population 
of approximately 314 million persons (Table 1). Surveillance was conducted in all states for Salmonella (typhoidal 
and non-typhoidal), Shigella, Escherichia coli O157, and Vibrio species other than V. cholerae. For 
Campylobacter, surveillance was conducted in the 10 states that comprise the Foodborne Diseases Active 
Surveillance Network (FoodNet), representing approximately 48 million persons (15% of the U.S. population).  
 
Clinically Important Antimicrobial Resistance Patterns 
 
In the United States, fluoroquinolones (e.g., ciprofloxacin) and third-generation cephalosporins (e.g., ceftriaxone) 
are commonly used to treat severe Salmonella infections, including typhoid and paratyphoid fever as well as 
severe non-typhoidal infections. In Enterobacteriaceae, (e.g., Salmonella and Shigella) resistance to nalidixic 
acid, an elementary quinolone, correlates with decreased susceptibility to ciprofloxacin (Table 2) and possible 
fluoroquinolone treatment failure. Macrolides (e.g., azithromycin), penicillins (e.g., ampicillin), and trimethoprim-
sulfamethoxazole are also of clinical importance. A substantial proportion of Enterobacteriaceae isolates tested in 
2012 demonstrated clinically important resistance. 
 
In Salmonella, antimicrobial resistance varies by serotype. Overall changes in resistance among non-typhoidal 
Salmonella may reflect changes in resistance within serotypes, changes in serotype distribution, or both.   
 3% (56/2236) of non-typhoidal Salmonella isolates were resistant to nalidixic acid. Enteriditis was the most 
common serotype among nalidixic acid-resistant non-typhoidal Salmonella isolates.   
o 50% (28/56) of nalidixic acid-resistant isolates were ser. Enteriditis 
o 8% (28/365) of ser. Enteriditis isolates were resistant to nalidixic acid 
 3% (65/2236) of non-typhoidal Salmonella isolates were resistant to ceftriaxone. The most common serotypes 
among the 65 ceftriaxone-resistant isolates were Newport, Typhimurium, Heidelberg and Dublin. Resistance 
occurred in  
o 7% (17/259) of ser. Newport isolates 
o 5% (16/295) of ser. Typhimurium isolates 
o 22% (9/41) of ser. Heidelberg isolates 
o 75% (6/8) of ser. Dublin isolates 
 68% (223/326) of Salmonella ser. Typhi isolates were resistant to nalidixic acid, and 6% (21/326) were 
resistant to ciprofloxacin. 
 95% (105/111) of Salmonella ser. Paratyphi A isolates were resistant to nalidixic acid, and 3% (3/111) were 
resistant to ciprofloxacin. 
 No Salmonella ser. Typhi or Salmonella ser. Paratyphi A isolates were resistant to ceftriaxone. 
 
In Shigella, fluoroquinolones and macrolides (e.g., azithromycin) are important agents in the treatment of severe 
infections. 
 2% (7/353) of Shigella isolates were resistant to ciprofloxacin, including 
o 2% (1/59) of Shigella flexneri isolates 
o 3% (6/287) of Shigella sonnei isolates 
 5% (16/353) of Shigella isolates were resistant to nalidixic acid, including 
o 5% (3/59) of Shigella flexneri isolates 
o 4% (12/287) of Shigella sonnei 
 4% (15/353) of Shigella isolates were resistant to azithromycin, including 
o 15% (9/59) of Shigella flexneri isolates 
o  2% (6/287) of Shigella sonnei isolates 
 
For Campylobacter, ECOFF values were used for interpreting antimicrobial susceptibility data. Since ECOFFs 
differ between Campylobacter species, the percent resistant for Campylobacter overall is not reported.  
 25% (301/1191) of Campylobacter jejuni isolates and 34% (45/134) of Campylobacter coli isolates were 
resistant to ciprofloxacin 
 2% (18/1191) of Campylobacter jejuni isolates and 9% (12/134) of Campylobacter coli isolates were resistant 
to erythromycin  
 6% (8/134) of Campylobacter coli isolates were resistant to gentamicin 







Multidrug resistance is reported in NARMS in several ways, including resistance to various numbers of classes of 
antimicrobial agents and also by specific co-resistance phenotypes. 
 
For non-typhoidal Salmonella, an important multidrug-resistance phenotype includes resistance to at least 
ampicillin, chloramphenicol, streptomycin, sulfonamide (sulfamethoxazole/sulfisoxazole), and tetracycline 
(ACSSuT); these agents represent five CLSI classes. Another important phenotype includes resistance to at least 
ampicillin, chloramphenicol, streptomycin, sulfonamide, tetracycline, amoxicillin-clavulanic acid, and ceftriaxone 
(ACSSuTAuCX); these agents represent seven CLSI classes.  
 4% (78/2236) of non-typhoidal Salmonella isolates were resistant to at least ACSSuT. The most common 
serotypes were Typhimurium, Newport, and Dublin.  ACSSuT resistance occurred in 
o 17% (50/295) ser. Typhimurium isolates 
o 4% (11/259) ser. Newport isolates 
o 88% (7/8) ser. Dublin isolates 
 
 2% (34/2236) of non-typhoidal Salmonella isolates were resistant to at least ACSSuTAuCx. The most 
common serotypes were Typhimurium, Newport, and Dublin.  ACSSuTAuCx resistance occurred in  
o 4% (11/295) ser. Typhimurium isolates  
o 4% (10/259) ser. Newport isolates 
o 75% (6/8) ser. Dublin isolates 
 9% (194/2236) of non-typhoidal Salmonella isolates were resistant to three or more CLSI classes. The most 
common serotypes with this resistance were Typhimurium, I,4,[5],12:i:, Newport, Enteritidis, Heidelberg, and 
Dublin. Resistance to three or more classes occurred in 
o 24% (72/295) ser. Typhimurium isolates  
o 28% (33/118) ser. I,4,[5],12:i:- isolates  
o 7% (17/259) ser. Newport isolates 
o 3% (11/365) ser. Enteriditis isolates  
o 27% (11/41) ser. Heidelberg isolates 
o 88% (7/8) ser. Dublin isolates 
 
For Salmonella ser. Typhi, an important multidrug-resistance phenotype includes resistance to at least ampicillin, 
chloramphenicol, and trimethoprim-sulfamethoxazole (ACT/S). 
 9% (30/326) of ser. Typhi isolates were resistant to at least ACT/S, and 10% (34/326) were resistant to three 
or more classes  
 
For Shigella, an important multidrug-resistance phenotype includes resistance to at least ampicillin and 
trimethoprim-sulfamethoxazole (AT/S). 
 16% (55/353) of Shigella isolates were resistant to at least AT/S, and 37% (132/353) were resistant to three 






Changes in Antimicrobial Resistance:  2012 vs. 2003–2007 
 
To understand changes in the prevalence of antimicrobial resistance among Salmonella, Shigella, and 
Campylobacter over time, we modelled annual data from 2003–2012 using logistic regression. Since 
2003, all 50 states have participated in Salmonella and Shigella surveillance and all 10 FoodNet sites in 
Campylobacter surveillance. We compared the prevalence of selected resistance patterns among 
isolates tested in 2012 with the average prevalence of resistance in 2003–2007. The methods are 
described in more detail in Surveillance and Laboratory Testing Methods. Because we defined the 
prevalence of resistance as the percentage of resistant isolates among total tested, changes in the 
prevalence of resistance described in this report do not necessarily reflect changes in the incidence of 
resistant infections. The incidence and relative changes in the incidence of Salmonella, Shigella, and 
Campylobacter infections are reported annually from surveillance in FoodNet sites (CDC, 2012).   
 
Figure H1.  Summary of trend analysis of the prevalence of selected resistance patterns among 














































































































































































































*   The reference is the average prevalence of resistance in 2003–2007. Logistic regression models adjusted for site. The odds   
     ratios (ORs) and 95% confidence intervals (CIs) for 2012 compared with the reference were calculated using unconditional   
     maximum likelihood estimation. ORs that do not include 1.0 in the 95% CIs are reported as statistically significant. 
†   Antimicrobial classes of agents are those defined by the Clinical and Laboratory Standards Institute (CLSI) 
‡   ACSSuT: resistance to at least ampicillin, chloramphenicol, streptomycin, sulfonamide, and tetracycline  
§   ACSSuTAuCx: resistance to at least ampicillin, chloramphenicol, streptomycin, sulfonamide, tetracycline, amoxicillin- 
















Changes in Antimicrobial Resistance:  2012 vs. 2003–2007 
The differences between the prevalence of resistance in 2012 and the average prevalence of 
resistance in 2003–2007 (Figure H1) were statistically significant for the following: 
 Among non-typhoidal Salmonella 
o Resistance to one or more CLSI classes was lower in 2012 than in 2003–2007 (15% vs. 20%; 
odds ratio [OR]=0.8, 95% confidence interval [CI] 0.7–0.9) 
o Resistance to three or more CLSI classes was lower in 2012 than in 2003–2007 (9% vs. 12%; 
OR=0.7, 95% CI 0.6–0.8) 
 Among Salmonella of particular serotypes 
o ACSSuTAuCx resistance in  ser. Newport was lower in 2012 than in  2003–2007 (4% vs. 13%; 
OR=0.3, 95% CI 0.1–0.5) 
o Ceftriaxone resistance in ser. Heidelberg was higher in 2012 than in 2003–2007 (22% vs. 8%; 
OR=3.6, 95% CI 1.6–8.1). It is important to note both that the number of isolates tested has 
been declining since 2008 and that only 9 isolates of 41 were resistant in 2012, so the 95% CI is 
wide. 
o Nalidixic acid resistance in ser. Typhi was higher in 2012 than in 2003–2007 (68% vs. 49%; 
OR=2.3, 95% CI 1.8–2.9)  
 Among Shigella spp. 
o Nalidixic acid resistance was higher in 2012 than in 2003–2007 (5% vs. 2%; OR=2.5, 95% CI 
1.3–4.6). Only 16 isolates of 353 were resistant in 2012, so the 95% CI is wide. 
 Among Campylobacter jejuni 
o Ciprofloxacin resistance was higher in 2012 than in 2003–2007 (25% vs. 21%; OR=1.4, 95% CI 
1.1–1.6) 
 
The differences between the prevalence of resistance in 2012 and the average prevalence of 
resistance in 2003–2007 (Figure H1) were not statistically significant for the following selected 
pathogen-resistance combinations: 
 Among non-typhoidal Salmonella  
o Ceftriaxone resistance (3% vs. 4%; OR=0.9, 95% CI 0.7–1.1) 
o Nalidixic acid resistance (3% vs. 2%; OR=1.2, 95% CI 0.9–1.7) 
 Among Salmonella of particular serotypes 
o Nalidixic acid resistance in ser. Enteritidis (8% vs. 6%; OR=1.4, 95% CI 0.9–2.2) 
o ACSSuT resistance in ser. Typhimurium (17% vs. 23%; OR=0.7, 95% CI 0.5–1.0) 





Introducing Epidemiological Cut-Off Values (ECOFFs) for the Interpretation of 
Campylobacter spp. Susceptibility Data  
 
  In this report, NARMS used a different approach for interpreting antimicrobial susceptibility data 
for Campylobacter than it has used previously. In previous reports, NARMS used clinical breakpoints 
from the Clinical and Laboratory Standards Institute (CLSI) to define susceptible (S), intermediate (I) 
and resistant (R) categories. In this report, NARMS instead used epidemiological cut-off values 
(ECOFFs) provided by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). 
This change facilitates detection of emerging resistance and is a step toward globally harmonized 
methods for Campylobacter surveillance. Below is a description of what ECOFFs are and how they 
differ from clinical breakpoints. 
An integral part of antimicrobial susceptibility testing is assigning the results to susceptible and 
resistant categories using interpretive criteria. The most commonly used criteria, the clinical 
breakpoints, are essential to guide correct clinical therapy and are also used for comparisons of 
resistance data between different monitoring programs. When determining clinical breakpoints, several 
kinds of data are considered, including Minimum Inhibitory Concentration (MIC) distribution data, 
clinical outcome data, and pharmacological properties of the drug at the site of infection. Since the 
primary purpose of clinical breakpoints is to guide therapy and predict clinical efficacy, they can have 
limitations for other purposes, such as detecting emerging resistance or conducting surveillance for 
emerging resistance. For instance, a breakpoint that appropriately predicts clinical efficacy might not 
provide the most sensitive detection of isolates that acquired a resistance mechanism. 
To facilitate detection of resistance, EUCAST has introduced the concept of ECOFFs to 
distinguish bacteria without resistance mechanisms (“wild type; (WT)”) from those with an acquired 
resistance mechanism (“non-wild type; NWT”). The ECOFF value for a given organism/drug 
combination is derived from analyses of MIC distribution data and is expressed as WT ≤ X mg/L. Thus, 
while the clinical breakpoint is set to guide therapy, ECOFFs are instead aimed at optimizing the 
detection of isolates with acquired resistance. ECOFFS do not take into consideration any data on 
dosages or clinical efficacy. An isolate which is considered non-wild type using ECOFFs may still be 
considered susceptible using clinical breakpoints (Figure H2). ECOFFs have been determined for a 
large number of organisms and drugs. Information on ECOFFs can be found on the EUCAST webpage 
(http://www.eucast.org/).  
 In this report NARMS has used the EUCAST ECOFFs to interpret results for Campylobacter, 
including historical data as well as data collected in 2012. To highlight the fact that wild type isolates 
are “microbiologically susceptible” and non-wild type isolates “microbiologically resistant”, isolates are 
being reported as “susceptible” or “resistant” (rather than “wild type” or “non-wild type”) in the present 
report. Thus, tables in this report that describe number and percentage resistant, resistance patterns, 






Introducing Epidemiological Cut-Off Values (ECOFFs) for the Interpretation of 
Campylobacter spp. Susceptibility Data  
 
 
Figure H2. Constructed example illustrating the difference between clinical breakpoints and 
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Surveillance Sites and Isolate Submissions  
 
In 2012, NARMS conducted nationwide surveillance among approximately 314 million persons (2012 estimates 
published in the 2013 U.S. Census Bureau report). Public health laboratories systematically selected every 20
th
 
non-typhoidal Salmonella, Shigella, and Escherichia coli O157 isolate and every Salmonella ser. Typhi, 
Salmonella ser. Paratyphi A, and Salmonella ser. Paratyphi C isolate received at their laboratories and forwarded 
these isolates to CDC for antimicrobial susceptibility testing. Salmonella ser. Paratyphi B was included in the 
sampling for non-typhoidal Salmonella because laboratory methods are not always available to reliably distinguish 
between ser. Paratyphi B (which typically causes typhoidal illness) and ser. Paratyphi B var. L(+) tartrate+ (which 
does not typically cause typhoidal illness). Serotype Paratyphi B isolates for which the results of tartrate 
fermentation testing are reported as either “negative” or “missing” are retested and confirmed at CDC. Those 
identified as ser. Paratyphi B var. L(+) tartrate+ are included with other nontyphoidal Salmonella serotypes in this 
report. Because the number of ser. Paratyphi B (tartrate negative) and ser. Paratyphi C isolates is very small, this 
report includes susceptibility results only for ser. Paratyphi A. Beginning in 2009, NARMS also performed 
susceptibility testing on isolates of Vibrio species other than V. cholerae submitted by the NARMS participating 
public health laboratories. Participants were asked to forward every Vibrio isolate that they received to CDC. 
Isolates of Vibrio cholerae are characterized in CDC’s National Enteric Reference Laboratory. Isolates of species 
other than V. cholerae are confirmed in the Reference Laboratory and tested for antimicrobial susceptibility by 
NARMS. For Information on toxigenic Vibrio cholerae, refer to the Cholera and Other Vibrio Illness Surveillance 
System (COVIS) annual summaries. 
 
Since 2005, public health laboratories of the 10 state health departments that participate in CDC’s Foodborne 
Diseases Active Surveillance Network (FoodNet) have forwarded a sample of Campylobacter isolates received to 
CDC for susceptibility testing. The FoodNet sites, representing approximately 48 million persons (2012 estimates 
published in 2013 U.S. Census Bureau report), include Connecticut, Georgia, Maryland, Minnesota, New Mexico, 
Oregon, Tennessee, and selected counties in California, Colorado, and New York. NARMS uses a sampling 
scheme for Campylobacter based on the number of isolates received by each FoodNet site. All isolates received 
by Oregon and Tennessee; every other isolate from California, Colorado, Connecticut, Georgia, Maryland, and 
New York; every third isolate from New Mexico; and every fifth isolate from Minnesota are submitted to CDC and 
tested. From 2005 to 2009, however, all isolates from Georgia, Maryland, and New Mexico were tested. From 
1997 to 2004, one Campylobacter isolate was submitted each week from participating FoodNet sites.  
  




Table 1. Population size and number of isolates received and tested, NARMS, 2012
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
4,817,528 (1.5) 72 (3.2) 1 (0.2) 16 (4.5) 1 (0.6) 3 (0.5)
730,307 (0.2) 2 (0.1) 0 (0) 1 (0.3) 1 (0.6) 0 (0)
6,551,149 (2.1) 46 (2.1) 9 (2.1) 0 (0) 1 (0.6) 8 (1.3)
2,949,828 (0.9) 28 (1.3) 0 (0) 1 (0.3) 2 (1.2) 0 (0)
28,037,089 (8.9) 165 (7.4) 71 (16.2) 2 (0.6) 8 (4.8) 66 (4.9) 79 (13.1)
5,189,458 (1.7) 29 (1.3) 6 (1.4) 6 (1.7) 5 (3.0) 38 (2.8) 11 (1.8)
3,591,765 (1.1) 25 (1.1) 4 (0.9) 4 (1.1) 3 (1.8) 129 (9.5) 22 (3.6)
917,053 (0.3) 9 (0.4) 0 (0) 1 (0.3) 0 (0) 5 (0.8)
633,427 (0.2) 18 (0.8) 0 (0) 9 (2.5) 0 (0) 0 (0)
19,320,749 (6.2) 29 (1.3) 11 (2.5) 5 (1.4) 1 (0.6) 91 (15.1)
9,915,646 (3.2) 139 (6.2) 12 (2.7) 26 (7.4) 6 (3.6) 238 (17.5) 17 (2.8)
1,390,090 (0.4) 12 (0.5) 5 (1.1) 3 (0.8) 2 (1.2) 26 (4.3)
2,160,821 (0.7) 51 (2.3) 15 (3.4) 11 (3.1) 1 (0.6) 0 (0)
1,595,590 (0.5) 8 (0.4) 0 (0) 1 (0.3) 4 (2.4) 1 (0.2)
12,868,192 (4.1) 105 (4.7) 18 (4.1) 18 (5.1) 11 (6.6) 3 (0.5)
6,537,782 (2.1) 43 (1.9) 3 (0.7) 4 (1.1) 10 (6.0) 2 (0.3)
3,075,039 (1.0) 26 (1.2) 2 (0.5) 5 (1.4) 4 (2.4) 0 (0)
2,885,398 (0.9) 15 (0.7) 1 (0.2) 2 (0.6) 1 (0.6) 1 (0.2)
4,379,730 (1.4) 32 (1.4) 0 (0) 4 (1.1) 0 (0) 0 (0)
9,962,789 (3.2) 58 (2.6) 9 (2.1) 2 (0.6) 0 (0) 0 (0)
4,602,134 (1.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
1,328,501 (0.4) 0 (0) 0 (0) 0 (0) 0 (0) 5 (0.8)
5,884,868 (1.9) 58 (2.6) 16 (3.7) 7 (2.0) 1 (0.6) 221 (16.3) 25 (4.1)
6,645,303 (2.1) 54 (2.4) 15 (3.4) 7 (2.0) 4 (2.4) 35 (5.8)
9,882,519 (3.1) 46 (2.1) 11 (2.5) 12 (3.4) 4 (2.4) 2 (0.3)
5,379,646 (1.7) 41 (1.8) 6 (1.4) 19 (5.4) 7 (4.2) 185 (13.6) 8 (1.3)
2,986,450 (1.0) 55 (2.5) 1 (0.2) 11 (3.1) 2 (1.2) 8 (1.3)
6,024,522 (1.9) 59 (2.6) 3 (0.7) 6 (1.7) 6 (3.6) 6 (1)
1,005,494 (0.3) 4 (0.2) 0 (0) 1 (0.3) 1 (0.6) 1 (0.2)
1,855,350 (0.6) 12 (0.5) 0 (0) 9 (2.5) 3 (1.8) 0 (0)
2,754,354 (0.9) 11 (0.5) 1 (0.2) 3 (0.8) 0 (0) 2 (0.3)
1,321,617 (0.4) 9 (0.4) 1 (0.2) 1 (0.3) 0 (0) 2 (0.3)
8,867,749 (2.8) 58 (2.6) 22 (5.0) 32 (9.1) 4 (2.4) 23 (3.8)
2,083,540 (0.7) 17 (0.8) 2 (0.5) 4 (1.1) 0 (0) 89 (6.5) 0 (0)
11,239,428 (3.6) 72 (3.2) 31 (7.1) 30 (8.5) 7 (4.2) 178 (13.1) 60 (10.0)
8,336,697 (2.7) 66 (3.0) 59 (13.5) 16 (4.5) 4 (2.4) 12 (2.0)
9,748,364 (3.1) 0 (0) 0 (0) 0 (0) 0 (0) 14 (2.3)
701,345 (0.2) 4 (0.2) 1 (0.2) 1 (0.3) 1 (0.6) 0 (0)
11,553,031 (3.7) 71 (3.2) 13 (3.0) 11 (3.1) 11 (6.6) 7 (1.2)
3,815,780 (1.2) 36 (1.6) 0 (0) 3 (0.8) 2 (1.2) 0 (0)
3,899,801 (1.2) 24 (1.1) 4 (0.9) 5 (1.4) 6 (3.6) 143 (10.5) 16 (2.7)
12,764,475 (4.1) 78 (3.5) 14 (3.2) 6 (1.7) 4 (2.4) 7 (1.2)
1,050,304 (0.3) 6 (0.3) 2 (0.5) 1 (0.3) 1 (0.6) 6 (1.0)
4,723,417 (1.5) 64 (2.9) 4 (0.9) 2 (0.6) 1 (0.6) 2 (0.3)
834,047 (0.3) 9 (0.4) 0 (0) 1 (0.3) 2 (1.2) 0 (0)
6,454,914 (2.1) 52 (2.3) 3 (0.7) 8 (2.3) 5 (3.0) 73 (5.4) 8 (1.3)
23,899,975 (7.6) 211 (9.4) 22 (5.0) 15 (4.2) 2 (1.2) 27 (4.5)
2,854,871 (0.9) 14 (0.6) 2 (0.5) 1 (0.3) 4 (2.4) 0 (0)
625,953 (0.2) 5 (0.2) 0 (0) 1 (0.3) 0 (0) 0 (0)
8,186,628 (2.6) 58 (2.6) 12 (2.7) 3 (0.8) 2 (1.2) 13 (2.2)
6,895,318 (2.2) 39 (1.7) 20 (4.6) 8 (2.3) 6 (3.6) 43 (7.1)
1,856,680 (0.6) 36 (1.6) 0 (0) 2 (0.6) 6 (3.6) 0 (0)
5,724,554 (1.8) 48 (2.1) 6 (1.4) 5 (1.4) 7 (4.2) 2 (0.3)
576,626 (0.2) 7 (0.3) 0 (0) 1 (0.3) 2 (1.2) 0 (0)



































































2012 population estimates published in 2013 U.S. Census Bureau population estimates
Typhoidal Salmonella  includes serotypes Typhi, Paratyphi A, Paratyphi B (tartrate negative), and Paratyphi C. Because the number of ser. Paratyphi B (tartrate 
negative) and ser. Paratyphi C isolates is very small, this report includes susceptibility results only for ser. Typhi and ser. Paratyphi A.
Campylobacter  isolates are submitted only from FoodNet sites w hich include Connecticut, Georgia, Maryland, Minnesota, New  Mexico, Oregon, Tennessee, and 
selected counties in California, Colorado, and New  York.  Of the clinical laboratories in each site that perform on-site testing for Campylobacter  (range,18 to 94 per 
site in 2012), the number submitting isolates to the state public health laboratory ranged from one to ninety-four.
Excluding Los Angeles County
Houston City
Los Angeles County
Excluding New  York City
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Testing of Salmonella, Shigella, and Escherichia coli O157  
 
Antimicrobial Susceptibility Testing 
 
Salmonella, Shigella, and E. coli O157 isolates were tested using broth microdilution (Sensititre®, Trek 
Diagnostics, part of Thermo Fisher Scientific, Cleveland, OH) according to manufacturer’s instructions to 
determine the MICs for each of 15 antimicrobial agents:  ampicillin, amoxicillin-clavulanic acid, azithromycin, 
cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, 
streptomycin, sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole (Table 2). Interpretive criteria 
defined by CLSI were used when available. Before 2004, sulfamethoxazole was used instead of sulfisoxazole to 
represent the sulfonamides. In 2011, azithromycin replaced amikacin on the panel of drugs tested for Salmonella, 
Shigella, and E. coli O157, so only historical susceptibility data are provided for amikacin. 
 
In January 2010, CLSI published revised interpretive criteria for ceftriaxone and Enterobacteriaceae; the revised 
resistance breakpoint for ceftriaxone is MIC ≥4 μg/mL. Since the 2009 report, NARMS has applied the revised 
CLSI breakpoint for ceftriaxone resistance to data from all years. In January 2012, CLSI published revised 
ciprofloxacin breakpoints for invasive Salmonella infections. For those infections, ciprofloxacin susceptibility is 
defined as ≤0.06 µg/mL; the intermediate category is defined as 0.12 to 0.5 µg/mL; and resistance is defined as 
≥1 µg/mL. In 2013, CLSI decided to apply these ciprofloxacin breakpoints to all subspecies and serotypes of 
Salmonella (Table 2). 
 
Repeat testing of isolates was done based on criteria in Appendix B.  
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Table 2.  Antimicrobial agents used for susceptibility testing for Salmonella, Shigella, and Escherichia 
coli O157 isolates, NARMS, 1996–2012 














 0.5–64 ≤16 32 ≥64 
Gentamicin 0.25–16 ≤4 8 ≥16 
Kanamycin 8–64 ≤16 32 ≥64 
Streptomycin
§
 32–64 ≤32 N/A* ≥64 
β–lactam /  
β–lactamase  
inhibitor combinations 
Amoxicillin-clavulanic acid 1/0.5–32/16 ≤8/4 16/8 ≥32/16 
Piperacillin-tazobactam
¶









 0.06–128 ≤1 2 ≥4 
Cefoxitin 0.5–32 ≤8 16 ≥32 
Ceftazidime
¶
 0.06–128 ≤4 8 ≥16 
Ceftiofur 0.12–8 ≤2 4 ≥8 
Ceftriaxone** 0.25–64 ≤1 2 ≥4 
Cephalothin
††





 16–512 ≤256 N/A* ≥512 
Sulfisoxazole 16–256 ≤256 N/A* ≥512 
Trimethoprim- 
sulfamethoxazole 
0.12/2.38–4/76 ≤2/38 N/A* ≥4/76 
Macrolides Azithromycin
§§
 0.12-16 ≤16 N/A* ≥32 
Monobactams Aztreonam
¶
 0.06–32 ≤4 8 ≥16 
Penems Imipenem
¶
 0.06–16 ≤1 2 ≥4 
Penicillins Ampicillin 1–32 ≤8 16 ≥32 
Phenicols Chloramphenicol 2–32 ≤8 16 ≥32 
Quinolones 
Ciprofloxacin 
 (Shigella and E. coli O157)  
0.015–4 ≤1 2 ≥4 
Ciprofloxacin  
(Salmonella spp.) 
0.015-4 ≤0.06 0.12-0.5 ≥1 
Nalidixic acid 0.5–32 ≤16 N/A* ≥32 
Tetracyclines Tetracycline 4–32 ≤4 8 ≥16 
*    N/A indicates that no MIC range of intermediate susceptibility exists 
†   Cefepime MICs above the susceptible range, but below the resistant range are now designated by CLSI to be S-DD. 
‡   Amikacin was tested from 1997 to 2010 for Salmonella, Shigella, and E. coli O157 
§   No CLSI breakpoints; resistance breakpoint used in NARMS is ≥64 µg/mL 
¶   Broad-spectrum β-lactam antimicrobial agent only tested for non-typhoidal Salmonella isolates displaying ceftriaxone       
     and/or ceftiofur resistance 
**  CLSI updated the ceftriaxone interpretive standards in January, 2010. NARMS Human Isolate Reports for 1996 through        
     2008 used susceptible ≤8 µg/mL, intermediate 16-32 µg/mL, and resistant ≥64 µg/mL. 
†† Cephalothin was tested from 1996 to 2003 for Salmonella, Shigella, and E. coli O157 
‡‡ Sulfamethoxazole, which was tested during 1996–2003 to represent sulfonamides, was replaced by sulfisoxazole in 2004 
§§ CLSI breakpoints are not established for azithromycin. The azithromycin breakpoints used in this report are NARMS- 




Additional Testing of Salmonella Strains 
 
β-lactam Panel Testing 
Isolates displaying resistance to either ceftriaxone (MIC ≥4 μg/mL) or ceftiofur (MIC ≥8 μg/mL) on the Trek 
Sensititre® gram-negative panel were subsequently tested using broth microdilution on a Sensititre® β-lactam 
panel (Trek Diagnostics, part of Thermo Fisher Scientific, Cleveland, OH) according to manufacturer’s instruction. 
The panel contained additional broad-spectrum β-lactam drugs: aztreonam, cefepime, cefotaxime, ceftazidime, 
imipenem, and piperacillin-tazobactam (Table 2). Briefly, a suspension of each isolate was made in water to a 
McFarland standard equivalency of 0.5, 10uL of this suspension was then used to inoculate a 10mL tube of 
Muller-Hinton broth, 50uL of this inoculated broth was dosed into each well of the 96-well β-lactam panel plate, 
and results were read manually after 18-20 hours of incubation at 35°C. Quality control isolates for this testing 
were E. coli ATCC 25922, K. pneumoniae ATCC 700603, P. aeruginosa ATCC 27853, and S. aureus ATCC 
29213.  
 
Cephalosporin Retesting of Isolates from 1996-1998 
 
Some Salmonella isolates tested in NARMS during 1996 to 1998 had inconsistent cephalosporin susceptibility 
results. In particular, some isolates previously reported in NARMS as ceftiofur-resistant exhibited a low 
ceftriaxone MIC, and some did not exhibit an elevated MIC to other β-lactams. Because these findings suggested 
that some previously reported results were inaccurate, isolates of Salmonella tested in NARMS during 1996 to 
1998 that exhibited an MIC ≥2 μg/mL to ceftiofur or ceftriaxone were retested using the 2003 NARMS Sensititre
®
 




The Salmonella serotype reported by the submitting laboratory was used for reporting with few exceptions. The 
serotype was confirmed by CDC for isolates that underwent subsequent molecular analysis. Because of 
challenges in interpretation of tartrate fermentation assays, ability to ferment tartrate was confirmed for isolates 
reported as Salmonella ser. Paratyphi B by the submitting laboratory (ser. Paratyphi B is by definition unable to 
ferment L(+) tartrate). To distinguish Salmonella ser. Paratyphi B and ser. Paratyphi B var. L(+) tartrate+ (formerly 
ser. Java), CDC performed Jordan’s tartrate test or Kauffmann’s tartrate test or both tests on all Salmonella ser. 
Paratyphi B isolates from 1996 to 2012 for which the tartrate result was not reported or was reported to be 
negative. Isolates negative for tartrate fermentation by all assays conducted were categorized as ser. Paratyphi B; 
as noted above, because the number of ser. Paratyphi B (tartrate negative) is very small, this report does not 
include susceptibility results for this serotype.  Isolates that were positive for tartrate fermentation by either assay 
were categorized as ser. Paratyphi B var. L(+) tartrate+ and were included with other nontyphoidal Salmonella in 
this report. CDC did not confirm other biochemical reactions or somatic and flagellar antigens. 
 
Because of increased submissions of Salmonella ser. I 4,[5],12:i:- noted in previous years and recognition of the 
possibility that this serotype may have been underreported in previous years, isolates reported as serogroup B 
and tested in NARMS during 1996 to 2012 were reviewed; isolates that could be clearly identified as serogroup B, 
first-phase flagellar antigen “i” second phase flagellar antigen absent were categorized in this report as 




Testing of Campylobacter 
 
Changes in Sampling over Time 
 
Starting in 2005, four changes were made to the Campylobacter testing methodology. First, a surveillance 
scheme for selecting a more representative sample of Campylobacter isolates for submission by FoodNet sites 
was implemented. State public health laboratories within FoodNet sites receive Campylobacter isolates from 
reference and clinical laboratories in their state. Until 2005, FoodNet sites submitted the first isolate received each 
week. In 2005, they started submitting every isolate (Georgia, Maryland, New Mexico, Oregon, and Tennessee), 
every other isolate (California, Colorado, Connecticut, and New York), or every fifth isolate received (Minnesota). 
Starting in 2010, Georgia and Maryland submitted every other isolate, and New Mexico submitted every third. Of 
the clinical laboratories in each site that perform on-site testing for Campylobacter (range,18 to 94 per site in 
2012), the number submitting isolates to the state public health laboratory ranged from one to 94.  
 
Changes in Identification/Speciation and Antimicrobial Susceptibility Testing Over Time 
 
 
From 2003 to 2004, Campylobacter isolates were identified as C. jejuni or C. coli using BAX® System PCR Assay 
according to the manufacturer's instructions (DuPont   Wilmington, DE). Isolates not identified as C. jejuni or C. 
coli were further characterized by other PCR assays (Linton et al. 1996) or were characterized by the CDC 
National Campylobacter Reference Laboratory. From 1997 to 2002, methodology similar to that used from 2005 
to 2009 was used. 
 
From 2005 to 2010, isolates were confirmed as Campylobacter by determination of typical morphology and 
motility using dark-field microscopy and a positive oxidase test reaction. Identification of C. jejuni was performed 
using the hippurate hydrolysis test. Hippurate-positive isolates were identified as C. jejuni. Hippurate-negative 
isolates were further characterized with PCR assays with specific targets for C. jejuni (mapA or hipO gene), C. 
coli-specific ceuE gene (Linton et al. 1997, Gonzales et al. 1997, Pruckler et al. 2006), or other species-specific 
primers. In 2010, all C. jejuni and suspected C. coli isolates were also confirmed through a multiplex PCR 
(Vandamme et al. 1997). Additionally the ceuE PCR was not used in 2010.  
 
The methods for susceptibility testing of Campylobacter and criteria for interpreting the results have also changed 
during the course of NARMS surveillance. From 1997 to 2004, Etest® (AB bioMerieux, Solna, Sweden) was used 
for susceptibility testing of Campylobacter isolates. Campylobacter-specific CLSI interpretive criteria were used 
for erythromycin, ciprofloxacin, and tetracycline beginning with the 2004 NARMS annual report.  NARMS 
breakpoints were used for agents for which CLSI breakpoints were not available. Beginning in 2004, NARMS 
breakpoints were established based on the MIC distributions of NARMS isolates and the presence of known 
resistance genes or mutations. In pre-2004 annual reports, NARMS breakpoints used had been based on those 
available for other organisms. Establishment of breakpoints based on MIC distributions resulted in higher MIC 
breakpoints for azithromycin and erythromycin resistance compared with those reported in pre-2004 annual 
reports. Beginning in 2005, broth microdilution using the Sensititre® system (Trek Diagnostics, part of Thermo 
Fisher Scientific, Cleveland, OH) was performed according to manufacturer’s instructions to determine the MICs 
for nine antimicrobial agents: azithromycin, ciprofloxacin, clindamycin, erythromycin, florfenicol, gentamicin, 
nalidixic acid, telithromycin, and tetracycline (Table 3). CLSI recommendations for quality control were followed. 
The interpretive criteria listed in Table 3 have been applied to MIC data collected for all years so that resistance 
prevalence is comparable over time. In 2012, the criteria for interpretation of results were changed from the 
previously used breakpoints to European Committee on Antimicrobial Susceptibility Testing (EUCAST) 












MIC Interpretive Standard (µg/mL) 
C. jejuni C. coli 




≤2 ≥4 ≤2 ≥4 
Ketolides Telithromycin
†

















 0.016–256* ≤16 ≥32 ≤16 ≥32 













≤1 ≥2 ≤2 ≥4 
*  Etest dilution range used from 1997–2004 
† Telithromycin added to NARMS panel in 2005 




Testing of Vibrio species other than V. cholerae 
 
NARMS participating public health laboratories were asked to forward every Vibrio isolate that they received to 
CDC. Isolates of Vibrio cholerae are characterized in CDC’s National Enteric Reference Laboratory. Isolates of 
species other than V. cholerae are confirmed in the Reference Laboratory and tested for antimicrobial 
susceptibility by NARMS. Minimum inhibitory concentrations were determined by Etest® (AB bioMerieux, Solna, 
Sweden) according to manufacturer’s instructions for nine antimicrobial agents: ampicillin, cephalothin, 
chloramphenicol, ciprofloxacin, kanamycin, nalidixic acid, streptomycin, tetracycline, and trimethoprim-
sulfamethoxazole (Table 4). CLSI breakpoints specific for Vibrio species other than V. cholerae were available for 
ampicillin, ciprofloxacin, tetracycline, and trimethoprim-sulfamethoxazole. Frequency of isolates susceptible, 
intermediate, and resistant to those agents is shown in this report (Table 55). MIC distributions are shown for all 
agents tested. For information on toxigenic Vibrio cholerae, refer to the Cholera and Other Vibrio Illness 




















Table 4. Antimicrobial agents used for susceptibility testing of Vibrio species other than V. cholerae 







MIC Interpretive Standard (µg/mL) 
Susceptible Intermediate* Resistant 
Aminoglycosides 
Kanamycin 0.016-256 No CLSI or NARMS breakpoints 
Streptomycin 0.064-1024 No CLSI or NARMS breakpoints 
Cephems Cephalothin 0.016-256  No CLSI or NARMS breakpoints 
Folate pathway inhibitors 
Trimethoprim- 
sulfamethoxazole 
0.002-32 ≤2/38 N/A ≥4/76 
Penicillins Ampicillin 0.016-256 ≤8 16 ≥32 
Phenicols Chloramphenicol 0.016-256 No CLSI or NARMS breakpoints 
Quinolones 
Ciprofloxacin 0.002-32 ≤1 2 ≥4 
Nalidixic acid 0.016-256 No CLSI or NARMS breakpoints 
Tetracyclines Tetracycline 0.016-256 ≤4 8 ≥16 
 









For all pathogens, isolates were categorized as resistant, intermediate (if applicable), or susceptible. Analysis was 
restricted to the first isolate received per patient in the calendar year (per serotype for Salmonella, per species for 
Shigella and Campylobacter). If two or more Salmonella ser. Typhi isolates were received for the same patient, 
the first blood isolate or other isolate from a normally sterile site collected, was included in the analysis.  If no 
blood isolate or other isolate from a normally sterile site was submitted, the first isolate collected was included in 
analysis. The 95% confidence intervals (CIs) for the percentage resistant, which were calculated using the 
Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method, are included in the MIC distribution 
tables.  
 
In the analysis of antimicrobial class resistance among Salmonella, Shigella, and E. coli O157, nine CLSI 
classes (Table 2) were represented by the following 15 agents: amoxicillin-clavulanic acid, ampicillin, 
azithromycin, cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic 
acid, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole. Isolates 
that were not resistant to any of these 15 agents were considered to have no resistance detected. In the 
analysis of antimicrobial class resistance among Campylobacter, six CLSI classes were represented by 
azithromycin, ciprofloxacin, chloramphenicol/florfenicol, clindamycin, erythromycin, gentamicin, nalidixic acid, 
and tetracycline (Table 3). Campylobacter isolates that were not resistant to any of these agents were 
considered to have no resistance detected. 
 
Using logistic regression, we modelled annual data from 2003–2012 to assess changes in prevalence of 
antimicrobial resistance among Salmonella, Shigella, and Campylobacter isolates. Since 2003, all 50 states have 
participated in Salmonella and Shigella surveillance and all 10 FoodNet sites in Campylobacter surveillance. We 
compared the prevalence of resistance among isolates tested in 2012 with the average prevalence in 2003–2007. 
Because we defined the prevalence of resistance as the percentage of resistant isolates among all isolates 
tested, changes in the prevalence of resistance described in this report do not necessarily reflect changes in the 
incidence of resistant infections. The incidence and relative changes in the incidence of Salmonella, Shigella, and 
Campylobacter infections are reported annually from surveillance in FoodNet sites (CDC, 2012). Comparisons 
were made for the following: 
 




 Salmonella of particular serotypes 
o Salmonella ser. Enteritidis: resistance to nalidixic acid 
o Salmonella ser. Typhimurium: resistance to at least ACSSuT (ampicillin, chloramphenicol, 
streptomycin, sulfonamide, and tetracycline) 
o Salmonella ser. Newport: resistance to at least ACSSuTAuCx (ACSSuT, amoxicillin-clavulanic acid, 
and ceftriaxone) 
o Salmonella ser. Typhi: resistance to nalidixic acid 
 Shigella: resistance to nalidixic acid 
 Campylobacter species: resistance to ciprofloxacin 
o Campylobacter jejuni: resistance to ciprofloxacin 
 
To account for site-to-site variation in the prevalence of antimicrobial resistance, we included main effects 
adjustments for site in the analysis. The final regression models for Salmonella and Shigella adjusted for the 
submitting site using the nine geographic regions described by the U.S. Census Bureau: East North Central, East 
South Central, Mid-Atlantic, Mountain, New England, Pacific, South Atlantic, West North Central, and West South 
Central. For Campylobacter, the final regression models adjusted for the submitting FoodNet site. Odds ratios 
(ORs) and 95% confidence intervals (CIs) were calculated using unconditional maximum likelihood estimation. 
The adequacy of model fit was assessed in several ways (Fleiss et al., 2004; Kleinbaum et al., 2008). The 
significance of the main effect of year was assessed using the likelihood ratio test. The likelihood ratio test was 
also used to test for significance of interaction between site and year, although the power of the test to detect a 
single site-specific interaction was low. When the main effect of year was significant, we report ORs with 95% CIs 




MIC Distribution Tables and Proportional Figures 
 
An explanation of “how to read a squashtogram” has been provided to assist the reader with the table (Figure 1). 
A squashtogram shows the distribution of MICs for antimicrobial agents tested. Proportional figures visually 
display data from squashtograms for an immediate comparative summary of resistance in specific pathogens and 
serotypes. These figures are a visual aid for the interpretation of MIC values. For most antimicrobial agents 
tested, three categories (susceptible, intermediate, and resistant) are used to interpret MICs. The proportion 
representing each category is shown in a horizontal proportional bar chart (Figure 2). 
 




%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Amikacin 0.0 0.0 [0.0–0.2] 7.4 70.1 20.8 1.6 0.1
Gentamicin 0.1 2.1 [1.5–2.8] 53.5 41.4 2.8 0.1 0.1 0.9 1.2
Streptomycin N/A 10.4 [9.1–11.7] 89.6 4.4 6.0
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 4.2 3.3 [2.6–4.1] 84.8 4.9 0.4 2.5 4.2 0.6 2.7
Cephems Ceftiofur 0.0 3.2 [2.6–4.1] 0.3 0.8 27.5 66.7 1.4 0.1 3.1
Ceftriaxone 2.3 0.4 [0.2–0.8] 96.7 0.1 0.5 1.4 0.9 0.3 0.1
Penicillins Ampicillin 0.0 10.1 [8.9–11.5] 81.2 8.3 0.3 0.1 0.1 10.0
Quinolones Ciprofloxacin 0.0 0.1 [0.0–0.3] 92.9 4.4 0.2 1.3 0.8 0.3 0.1
Nalidixic acid N/A 2.2 [1.7–3.0] 0.1 0.2 34.4 61.9 0.9 0.2 2.2
Aminoglycosides Kanamycin < 0.1 2.8 [2.2–3.6] 96.8 0.2 < 0.1 0.2 2.6
Cephems Cefoxitin 0.7 3.0 [2.3–3.7] 0.2 8.8 70.2 15.8 1.3 0.7 0.9 2.1
Folate pathway inhibitors Sulfisoxazole N/A 12.3 [11.0–13.8] 19.0 53.1 15.0 0.5 0.1 12.3
Trimethoprim-sulfamethoxazole N/A 1.6 [1.1–2.2] 79.7 18.3 0.2 0.2 0.1 1.5
Phenicols Chloramphenicol 0.7 7.3 [6.2–8.5] 0.8 41.7 49.5 0.7 0.4 6.9
Tetracyclines Tetracycline 0.1 14.5 [13.0–16.0] 85.4 0.1 0.9 4.2 9.4
CLSI† Antimicrobial Class Antimicrobial Agent
II











95% confidence interval 
for percent resistant
Sum of percents = 
% susceptible
Sum of percents = 
% intermediate
Sum of percents = 
% resistant
Single line is upper limit of 
susceptibility / lower limit of 
intermediate result
Double line is upper limit of 
intermediate result / lower limit 




Figure 2.  Proportional chart, a categorical graph of a squashtogram 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin <0.1 1.7 [1.2 - 2.3] 8.3 76.4 13.1 0.5 <0.1 0.2 1.5
Kanamycin <0.1 1.7 [1.2 - 2.3] 98.2 0.1 <0.1 <0.1 1.6
Streptomycin N/A 9.8 [8.6 - 11.1] 90.2 2.3 7.5
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 2.0 2.6 [2.0 - 3.3] 89.2 1.7 0.6 3.9 2.0 0.8 1.8
Cephems Ceftiofur <0.1 2.5 [1.9 - 3.2] 0.3 0.8 37.7 57.7 1.0 <0.1 0.2 2.3
Ceftriaxone <0.1 2.5 [1.9 - 3.2] 97.5 <0.1 0.1 0.3 1.0 0.8 0.3 0.1
Macrolide Azithromycin N/A 0.2 [0.1 - 0.5] 0.2 0.4 11.2 80.4 7.3 0.2 0.2
Penicillins Ampicillin 0.1 9.1 [8.0 - 10.3] 86.9 3.5 0.3 0.1 0.1 0.2 8.9
Quinolones Ciprofloxacin 2.8 0.2 [0.0 - 0.4] 91.9 4.9 0.2 1.0 0.9 0.9 0.1 0.1
Nalidixic acid N/A 2.4 [1.8 - 3.1] 0.2 0.6 47.4 48.1 0.9 0.4 0.1 2.3
Cephems Cefoxitin 0.2 2.6 [2.0 - 3.3] 0.4 31.1 53.7 10.7 1.3 0.2 1.1 1.5
Folate pathway inhibitors Sulfisoxazole N/A 8.6 [7.5 - 9.8] 5.9 46.1 37.8 1.5 8.6
Trimethoprim-sulfamethoxazole N/A 1.2 [0.8 - 1.7] 96.8 1.7 0.2 <0.1 <0.1 1.2
Phenicols Chloramphenicol 0.6 4.4 [3.6 - 5.3] 0.9 51.0 43.1 0.6 0.1 4.3









Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank * CLSI† Antimicrobial Class Antimicrobial Agent
























1.  Non-typhoidal Salmonella 
 
Table 5.  Number of non-typhoidal Salmonella isolates of the 20 most common serotypes* tested by NARMS with the number of resistant isolates by 
class and agent, 2012 
N (%) 0 1 2–3 4–5 6–7 8 GEN KAN STR AMC FOX TIO AXO FIS COT AZI AMP CHL CIP NAL TET
365 (16.3) 321 25 13 6 0 0 0 0 7 3 3 3 3 10 4 0 16 2 0 28 13
295 (13.2) 203 6 25 50 9 2 9 6 70 16 15 16 16 79 5 0 69 53 1 5 79
259 (11.6) 240 1 7 0 11 0 0 0 11 16 16 17 17 11 2 0 19 11 0 0 12
134 (6.0) 131 1 2 0 0 0 0 0 1 0 0 0 0 1 0 0 2 1 0 0 1
118 (5.3) 73 8 6 31 0 0 3 0 34 2 1 1 1 34 0 0 34 0 0 1 39
89 (4.0) 83 3 2 0 1 0 0 1 0 1 1 2 2 2 3 0 2 0 0 3 3
60 (2.7) 56 3 1 0 0 0 1 0 1 0 0 0 0 1 0 0 0 0 0 0 3
58 (2.6) 56 0 2 0 0 0 0 0 1 0 0 0 0 2 0 0 0 0 0 0 1
51 (2.3) 50 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0
50 (2.2) 42 2 4 1 1 0 2 0 1 0 0 1 1 5 4 0 3 1 1 1 7
49 (2.2) 47 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 1 0 0 0 1
48 (2.1) 46 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 0 0 1
41 (1.8) 25 0 15 1 0 0 3 4 7 9 9 9 9 1 0 0 11 0 0 0 6
34 (1.5) 34 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
27 (1.2) 27 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
27 (1.2) 27 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
22 (1.0) 16 4 2 0 0 0 0 0 2 2 2 2 2 0 0 0 2 0 0 2 0
20 (0.9) 11 1 5 1 2 0 1 1 3 3 3 3 3 7 0 0 5 2 0 1 6
18 (0.8) 1 1 16 0 0 0 0 1 16 0 0 0 0 0 0 0 2 0 0 1 16
17 (0.8) 14 1 2 0 0 0 0 0 1 0 0 0 0 0 1 0 1 0 0 0 2
17 (0.8) 16 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0
16 (0.7) 11 0 5 0 0 0 1 0 2 0 0 0 0 2 2 0 3 0 0 0 5
15 (0.7) 12 1 2 0 0 0 2 2 2 0 0 0 0 2 0 0 0 0 0 0 3
14 (0.6) 14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
12 (0.5) 11 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
12 (0.5) 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
12 (0.5) 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
11 (0.5) 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
11 (0.5) 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
10 (0.4) 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
10 (0.4) 7 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3
10 (0.4) 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1932 (86.4) 1640 65 111 90 24 2 22 15 160 52 50 54 54 159 23 0 171 71 3 44 201
All other serotypes 251 (11.2) 206 11 17 4 10 3 4 9 24 12 10 11 10 26 7 0 22 15 5 11 41
Partially serotyped 27 (1.2) 24 0 0 2 1 0 0 0 3 1 1 1 1 3 0 0 3 2 0 0 3
7 (0.3) 5 2 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1
19 (0.8) 17 1 0 1 0 0 0 0 1 0 0 0 0 1 0 0 1 0 0 1 1















Only serotypes with at least 10 isolates are listed individually
CLSI: Clinical and Laboratory Standards Institute
Antimicrobial agent abbreviations: GEN, gentamicin; KAN, kanamycin; STR, streptomycin; AMC, amoxicillin-clavulanic acid; FOX, cefoxitin; TIO, ceftiofur; AXO, ceftriaxone; FIS, sulfisoxazole; COT, trimethoprim-sulfamethoxazole; AZI, azithromycin; 
AMP, ampicillin; CHL, chloramphenicol; CIP, ciprofloxacin; NAL, nalidixic acid; TET, tetracycline
Rough/Nonmotile isolates
Unknown serotype

























Number of Isolates Number of Resistant Isolates by CLSI
†























Table 6.  Percentage and number of non-typhoidal Salmonella isolates in NARMS with selected resistance 
patterns, by serotype, 2012 
N n (%) n (%) n (%) n (%) n (%) n (%)
Twenty most common serotypes
1 Enteritidis 365 0 (0) 0 (0) 0 (0) 28 (50.0) 3 (4.6) 0 (0)
2 Typhimurium 295 50 (64.1) 2 (25.0) 11 (32.4) 5 (8.9) 16 (24.6) 2 (33.3)
3 Newport 259 11 (14.1) 2 (25.0) 10 (29.4) 0 (0) 17 (26.2) 0 (0)
4 Javiana 134 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
5 I 4,[5],12:i:- 118 0 (0) 0 (0) 0 (0) 1 (1.8) 1 (1.5) 0 (0)
6 Infantis 89 0 (0) 0 (0) 0 (0) 3 (5.4) 2 (3.1) 1 (16.7)
7 Montevideo 60 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
8 Muenchen 58 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
9 Oranienburg 51 0 (0) 0 (0) 0 (0) 1 (1.8) 0 (0) 0 (0)
10 Saintpaul 50 0 (0) 0 (0) 0 (0) 1 (1.8) 1 (1.5) 0 (0)
11 Bareilly 49 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
12 Braenderup 48 0 (0) 1 (12.5) 0 (0) 0 (0) 0 (0) 0 (0)
13 Heidelberg 41 0 (0) 0 (0) 0 (0) 0 (0) 9 (13.8) 0 (0)
14 Thompson 34 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
15 Mississippi 27 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Paratyphi B var. L(+) tartrate+ 27 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
17 Schwarzengrund 22 0 (0) 0 (0) 0 (0) 2 (3.6) 2 (3.1) 0 (0)
18 Agona 20 2 (2.6) 0 (0) 2 (5.9) 1 (1.8) 3 (4.6) 0 (0)
19 Hadar 18 0 (0) 0 (0) 0 (0) 1 (1.8) 0 (0) 0 (0)
20 Litchfield 17 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Poona 17 0 (0) 0 (0) 0 (0) 1 (1.8) 0 (0) 0 (0)
Senftenberg 9 0 (0) 0 (0) 0 (0) 1 (1.8) 0 (0) 0 (0)
Dublin 8 7 (9.0) 1 (12.5) 6 (17.6) 1 (1.8) 6 (9.2) 1 (16.7)
Reading 8 1 (1.3) 1 (12.5) 0 (0) 0 (0) 0 (0) 0 (0)
Derby 7 1 (1.3) 0 (0) 1 (2.9) 0 (0) 1 (1.5) 0 (0)
Kentucky 7 1 (1.3) 0 (0) 0 (0) 3 (5.4) 0 (0) 0 (0)
Virchow 5 0 (0) 0 (0) 0 (0) 1 (1.8) 0 (0) 0 (0)
I 6,7:r:- 3 0 (0) 0 (0) 0 (0) 1 (1.8) 0 (0) 0 (0)
Blockley 2 1 (1.3) 1 (12.5) 1 (2.9) 0 (0) 1 (1.5) 0 (0)
Albert 1 1 (1.3) 0 (0) 1 (2.9) 1 (1.8) 1 (1.5) 1 (16.7)
Choleraesuis 1 1 (1.3) 0 (0) 1 (2.9) 1 (1.8) 1 (1.5) 1 (16.7)
I 4,[5],12:-:1,2 1 0 (0) 0 (0) 0 (0) 1 (1.8) 0 (0) 0 (0)
IIIa 50:z4,z23:- 1 0 (0) 0 (0) 0 (0) 1 (1.8) 0 (0) 0 (0)
1852 76 (97.4) 8 (100) 33 (97.1) 55 (98.2) 64 (98.5) 6 (100)
All other serotypes 331 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Partially serotyped 27 2 (2.6) 0 (0) 1 (2.9) 0 (0) 1 (1.5) 0 (0)
Rough/Nonmotile isolates 7 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Unknown serotype 19 0 (0) 0 (0) 0 (0) 1 (1.8) 0 (0) 0 (0)








ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, and ceftriaxone
CxN: resistance to ceftriaxone and nalidixic acid



















Table 7.  Percentage and number of non-typhoidal Salmonella isolates in NARMS with resistance, by 
number of CLSI* classes and serotype, 2012 
N n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Enteritidis 365 11 (5.7) 6 (4.4) 2 (2.2) 0 (0) 0 (0) 0 (0) 0 (0)
Typhimurium 295 72 (37.1) 61 (44.5) 54 (60.7) 11 (27.5) 11 (30.6) 2 (40.0) 0 (0)
Newport 259 17 (8.8) 11 (8.0) 11 (12.4) 11 (27.5) 10 (27.8) 0 (0) 0 (0)
Javiana 134 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
I 4,[5],12:i:- 118 33 (17.0) 31 (22.6) 1 (1.1) 0 (0) 0 (0) 0 (0) 0 (0)
Infantis 89 3 (1.5) 1 (0.7) 1 (1.1) 1 (2.5) 0 (0) 0 (0) 0 (0)
Montevideo 60 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Muenchen 58 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Oranienburg 51 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Saintpaul 50 3 (1.5) 2 (1.5) 1 (1.1) 1 (2.5) 0 (0) 0 (0) 0 (0)
Bareilly 49 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Braenderup 48 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Heidelberg 41 11 (5.7) 1 (0.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Thompson 34 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Mississippi 27 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Paratyphi B var. L(+) tartrate+ 27 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Schwarzengrund 22 2 (1.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Agona 20 5 (2.6) 3 (2.2) 2 (2.2) 2 (5.0) 2 (5.6) 0 (0) 0 (0)
Hadar 18 2 (1.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Litchfield 17 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Poona 17 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Stanley 16 2 (1.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Anatum 15 2 (1.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Dublin 8 7 (3.6) 7 (5.1) 7 (7.9) 7 (17.5) 7 (19.4) 1 (20.0) 0 (0)
Reading 8 2 (1.0) 1 (0.7) 1 (1.1) 0 (0) 0 (0) 0 (0) 0 (0)
Derby 7 4 (2.1) 2 (1.5) 1 (1.1) 1 (2.5) 1 (2.8) 0 (0) 0 (0)
Kentucky 7 2 (1.0) 2 (1.5) 2 (2.2) 2 (5.0) 1 (2.8) 0 (0) 0 (0)
Brandenburg 5 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Johannesburg 5 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Ohio 5 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Virchow 5 1 (0.5) 1 (0.7) 1 (1.1) 0 (0) 0 (0) 0 (0) 0 (0)
Uganda 4 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
I 6,7:r:- 3 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Blockley 2 1 (0.5) 1 (0.7) 1 (1.1) 1 (2.5) 1 (2.8) 0 (0) 0 (0)
Albert 1 1 (0.5) 1 (0.7) 1 (1.1) 1 (2.5) 1 (2.8) 1 (20.0) 0 (0)
Choleraesuis 1 1 (0.5) 1 (0.7) 1 (1.1) 1 (2.5) 1 (2.8) 1 (20.0) 0 (0)
I 4,[5],12:-:1,2 1 1 (0.5) 1 (0.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
1892 190 (97.9) 133 (97.1) 87 (97.8) 39 (97.5) 35 (97.2) 5 (100) 0 (0)
All other serotypes 291 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Partially serotyped 7 3 (1.5) 3 (2.2) 2 (2.2) 1 (2.5) 1 (2.8) 0 (0) 0 (0)
Rough/Nonmotile isolates 19 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Unknown serotype 27 1 (0.5) 1 (0.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
2236 194 (100) 137 (100) 89 (100) 40 (100) 36 (100) 5 (100) 0 (100)
* CLSI: Clinical and Laboratory Standards Institute

















≥ 6 CLSI classes*≥ 3 CLSI classes* ≥ 4 CLSI classes* ≥ 5 CLSI classes* ≥ 9 CLSI classes*
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Table 8.  Minimum inhibitory concentrations (MICs) and resistance of non-typhoidal Salmonella isolates 
to antimicrobial agents, 2012 (N=2236) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin <0.1 1.2 [0.8 - 1.7] 16.2 72.5 9.2 0.7 0.1 <0.1 0.3 0.9
Kanamycin 0.0 1.1 [0.7 - 1.6] 98.9 <0.1 1.0
Streptomycin N/A 8.4 [7.3 - 9.6] 91.6 2.7 5.7
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 2.6 2.9 [2.3 - 3.7] 89.3 1.7 0.9 2.6 2.6 0.2 2.7
Cephems Ceftiofur 0.1 3.0 [2.3 - 3.7] 0.3 0.6 23.7 70.7 1.7 0.1 0.2 2.8
Ceftriaxone <0.1 2.9 [2.3 - 3.7] 97.0 <0.1 <0.1 <0.1 0.2 1.0 1.2 0.3 0.1
Macrolide Azithromycin N/A <0.1 [0.0 - 0.2] 0.1 0.3 9.3 83.2 6.8 0.3 <0.1
Penicillins Ampicillin 0.1 8.8 [7.7 - 10.1] 86.4 4.2 0.4 <0.1 0.1 8.8
Quinolones Ciprofloxacin 3.3 0.4 [0.2 - 0.7] 89.6 6.5 0.3 1.1 1.3 1.0 0.2 0.1
Nalidixic acid N/A 2.5 [1.9 - 3.2] 0.1 0.6 40.2 54.4 1.3 0.8 0.2 2.3
Cephems Cefoxitin 0.2 2.7 [2.1 - 3.5] 0.1 17.7 62.4 15.1 1.7 0.2 0.9 1.8
Folate pathway inhibitors Sulfisoxazole N/A 8.5 [7.3 - 9.7] 8.8 50.4 31.6 0.7 0.1 8.5
Trimethoprim-sulfamethoxazole N/A 1.3 [0.9 - 1.9] 97.1 1.4 <0.1 <0.1 0.2 1.2
Phenicols Chloramphenicol 0.6 3.9 [3.2 - 4.8] 1.1 47.0 47.4 0.6 0.1 3.8









Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
























Antimicrobial Agent Susceptible, Intermediate, and Resistant Proportion 
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Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 































































































































































































































































































































At least ASSuT‡ and not resistant to 
chloramphenicol
At least AAuCx**
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least ACSSuT† 
At least ACT/S§
At least ACSSuTAuCx¶
At least ceftriaxone and nalidixic acid 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
AAuCx: resistance to ampicillin, amoxicillin-clavulanic acid, ceftriaxone
At least nalidixic acid and azithromycin 
resistant





No resistance detected 
Resistance ≥ 1 CLSI class*
Resistance ≥ 2 CLSI classes*





Table 11.  Broad-Spectrum β-lactam resistance among all ceftriaxone or ceftiofur resistant non-typhoidal 
Salmonella isolates, 2011–2012 
% I‡ (or S-DD§) %R¶ [95% CI]** 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512




2011 (58) 15.5 10.3 [3.9 - 21.2] 1.7 5.2 15.5 39.7 12.1 5.2 10.3 3.4 6.9
2012 (66) 9.1 6.1 [1.7 - 14.8] 6.1 12.1 54.5 12.1 7.6 1.5 3.0 3.0
Cephems Cefepime§ 2011 (58) (1.7§) 1.7 [0.0 - 9.2] 3.4 32.8 41.4 13.8 5.2 1.7§ 1.7
2012 (66) (6.1§) 0.0 [0.0 - 5.4] 1.5 13.6 54.5 16.7 7.6 3.0 3.0
Cefotaxime 2011 (58) 0.0 100 [93.8 - 100] 1.7 10.3 37.9 34.5 10.3 3.4 1.7
2012 (66) 0.0 100 [94.6 - 100] 4.5 4.5 48.5 34.8 4.5 1.5 1.5
Ceftazidime 2011 (58) 3.4 96.6 [88.1 - 99.6] 3.4 22.4 53.4 12.1 6.9 1.7
2012 (66) 4.5 87.9 [77.5 - 94.6] 1.5 6.1 4.5 39.4 36.4 9.1 3.0
Monobactams Aztreonam 2011 (58) 43.1 41.4 [28.6 - 55.1] 6.9 8.6 43.1 27.6 8.6 5.2
2012 (66) 54.5 27.3 [17.0 - 39.6] 1.5 1.5 1.5 13.6 54.5 18.2 7.6 1.5
Penems Imipenem 2011 (58) 0.0 1.7 [0.0 - 9.2] 1.7 77.6 19.0 1.7








Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility
Percentage of isolates that are susceptible-dose dependent (S-DD). Cefepime MICs above the susceptible range but below  the resistant range are now  designated by CLSI to be S-DD. Corresponding dilution ranges are 
shaded in orange.
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Clopper-Pearson exact method
The unshaded and orange-shaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Orange-shaded areas also indicate the dilution range for susceptible-dose dependent (S-DD). Single vertical 
bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the gray shaded areas indicate the percentages of isolates w ith MICs greater than the highest 
concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to or less than the low est tested concentration. CLSI breakpoints w ere used 
w hen available.













A. Salmonella ser. Enteritidis 
 
Table 12.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Enteritidis isolates 
to antimicrobial agents, 2012 (N=365) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.0 [0.0 - 1.0] 45.2 51.8 2.5 0.5
Kanamycin 0.0 0.0 [0.0 - 1.0] 100.0
Streptomycin N/A 1.9 [0.8 - 3.9] 98.1 0.3 1.6
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.3 0.8 [0.2 - 2.4] 92.6 2.7 0.3 3.3 0.3 0.8
Cephems Ceftiofur 0.3 0.8 [0.2 - 2.4] 0.5 1.4 4.7 88.8 3.6 0.3 0.8
Ceftriaxone 0.0 0.8 [0.2 - 2.4] 99.2 0.3 0.5
Macrolide Azithromycin N/A 0.0 [0.0 - 1.0] 0.3 0.5 9.9 84.1 4.9 0.3
Penicillins Ampicillin 0.0 4.4 [2.5 - 7.0] 80.0 14.0 1.4 0.3 4.4
Quinolones Ciprofloxacin 7.9 0.0 [0.0 - 1.0] 61.6 30.1 0.3 4.7 3.0 0.3
Nalidixic acid N/A 7.7 [5.2 - 10.9] 0.3 1.4 14.5 74.0 1.9 0.3 0.3 7.4
Cephems Cefoxitin 0.5 0.8 [0.2 - 2.4] 11.5 70.7 15.1 1.4 0.5 0.3 0.5
Folate pathway inhibitors Sulfisoxazole N/A 2.7 [1.3 - 5.0] 7.1 52.9 37.0 0.3 2.7
Trimethoprim-sulfamethoxazole N/A 1.1 [0.3 - 2.8] 97.5 1.4 1.1
Phenicols Chloramphenicol 0.0 0.5 [0.1 - 2.0] 1.1 52.6 45.8 0.3 0.3









Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
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Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
































































































































































































































































































































No resistance detected 
Resistance ≥ 1 CLSI class*
Resistance ≥ 2 CLSI classes*
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 




Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least ACSSuT† 











B. Salmonella ser. Typhimurium 
 
Table 15.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Typhimurium 
isolates to antimicrobial agents, 2012 (N=295) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 3.1 [1.4 - 5.7] 7.8 76.6 11.2 1.0 0.3 0.7 2.4
Kanamycin 0.0 2.0 [0.7 - 4.4] 98.0 2.0
Streptomycin N/A 23.7 [19.0 - 29.0] 76.3 7.5 16.3
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 15.3 5.4 [3.1 - 8.7] 74.6 2.0 0.3 2.4 15.3 0.3 5.1
Cephems Ceftiofur 0.0 5.4 [3.1 - 8.7] 0.3 16.6 75.3 2.4 0.7 4.7
Ceftriaxone 0.0 5.4 [3.1 - 8.7] 94.2 0.3 1.7 2.4 1.4
Macrolide Azithromycin N/A 0.0 [0.0 - 1.2] 5.1 92.5 2.4
Penicillins Ampicillin 0.0 23.4 [18.7 - 28.6] 72.2 4.1 0.3 23.4
Quinolones Ciprofloxacin 1.4 0.3 [0.0 - 1.9] 96.9 1.4 0.3 0.7 0.3 0.3
Nalidixic acid N/A 1.7 [0.5 - 3.9] 0.7 42.7 54.2 0.7 0.3 1.4
Cephems Cefoxitin 0.3 5.1 [2.9 - 8.2] 0.3 14.9 70.2 6.8 2.4 0.3 2.7 2.4
Folate pathway inhibitors Sulfisoxazole N/A 26.8 [21.8 - 32.2] 5.4 59.0 8.1 0.3 0.3 26.8
Trimethoprim-sulfamethoxazole N/A 1.7 [0.5 - 3.9] 94.2 4.1 0.3 1.4
Phenicols Chloramphenicol 0.7 18.0 [13.8 - 22.8] 0.3 44.4 36.6 0.7 0.3 17.6









Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
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Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
































































































































































































































































































































At least ACSSuT† 





Resistance ≥ 1 CLSI class*
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*




No resistance detected 
At least ceftriaxone and nalidixic acid 
resistant
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 




C. Salmonella ser. Newport 
 
Table 18.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Newport isolates 
to antimicrobial agents, 2012 (N=259) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.0 [0.0 - 1.4] 8.5 84.9 6.2 0.4
Kanamycin 0.0 0.0 [0.0 - 1.4] 100.0
Streptomycin N/A 4.2 [2.1 - 7.5] 95.8 4.2
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.8 6.2 [3.6 - 9.8] 91.5 0.8 0.4 0.4 0.8 6.2
Cephems Ceftiofur 0.0 6.6 [3.9 - 10.3] 19.3 74.1 6.6
Ceftriaxone 0.0 6.6 [3.9 - 10.3] 93.4 2.3 2.7 1.2 0.4
Macrolide Azithromycin N/A 0.0 [0.0 - 1.4] 0.8 17.4 77.6 4.2
Penicillins Ampicillin 0.4 7.3 [4.5 - 11.2] 91.1 1.2 0.4 7.3
Quinolones Ciprofloxacin 3.1 0.0 [0.0 - 1.4] 96.1 0.8 3.1
Nalidixic acid N/A 0.0 [0.0 - 1.4] 0.4 39.0 56.8 0.8 3.1
Cephems Cefoxitin 0.0 6.2 [3.6 - 9.8] 18.9 70.3 3.5 1.2 1.9 4.2
Folate pathway inhibitors Sulfisoxazole N/A 4.2 [2.1 - 7.5] 4.2 35.5 55.6 0.4 4.2
Trimethoprim-sulfamethoxazole N/A 0.8 [0.1 - 2.8] 98.8 0.4 0.8
Phenicols Chloramphenicol 0.0 4.2 [2.1 - 7.5] 0.8 72.6 22.4 4.2









Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
























Antimicrobial Agent Susceptible, Intermediate, and Resistant Proportion 
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Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 




































































































































































































































































































































No resistance detected 
Resistance ≥ 1 CLSI class*
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least ACSSuT† 




At least ceftriaxone and nalidixic acid 
resistant
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 




D. Salmonella ser. Heidelberg  
 
Table 21.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Heidelberg 
isolates to antimicrobial agents, 2012 (N=41) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 7.3 [1.5 - 19.9] 4.9 70.7 17.1 7.3
Kanamycin 0.0 9.8 [2.7 - 23.1] 90.2 9.8
Streptomycin N/A 17.1 [7.1 - 32.1] 82.9 12.2 4.9
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.0 22.0 [10.5 - 37.6] 70.7 2.4 4.9 22.0
Cephems Ceftiofur 0.0 22.0 [10.5 - 37.6] 29.3 46.3 2.4 22.0
Ceftriaxone 0.0 22.0 [10.5 - 37.6] 78.0 14.6 4.9 2.4
Macrolide Azithromycin N/A 0.0 [0.0 - 8.6] 2.4 97.6
Penicillins Ampicillin 0.0 26.8 [14.2 - 42.9] 70.7 2.4 26.8
Quinolones Ciprofloxacin 2.4 0.0 [0.0 - 8.6] 95.1 2.4 2.4
Nalidixic acid N/A 0.0 [0.0 - 8.6] 12.2 85.4 2.4
Cephems Cefoxitin 0.0 22.0 [10.5 - 37.6] 39.0 36.6 2.4 9.8 12.2
Folate pathway inhibitors Sulfisoxazole N/A 2.4 [0.0 - 12.8] 17.1 63.4 17.1 2.4
Trimethoprim-sulfamethoxazole N/A 0.0 [0.0 - 8.6] 100.0
Phenicols Chloramphenicol 0.0 0.0 [0.0 - 8.6] 2.4 24.4 73.2









Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
























Antimicrobial Agent Susceptible, Intermediate, and Resistant Proportion 
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Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
































































































































































































































































































































No resistance detected 
Resistance ≥ 1 CLSI class*
Resistance ≥ 2 CLSI classes*
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 




Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least ACSSuT† 











E. Salmonella ser. I 4,[5],12:i:- 
 
Table 24.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. I 4,[5],12:i:- 
isolates to antimicrobial agents, 2012 (N=118) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 2.5 [0.5 - 7.2] 2.5 80.5 13.6 0.8 0.8 1.7
Kanamycin 0.0 0.0 [0.0 - 3.1] 100.0
Streptomycin N/A 28.8 [20.8 - 37.9] 71.2 1.7 27.1
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.0 1.7 [0.2 - 6.0] 70.3 0.8 9.3 17.8 0.8 0.8
Cephems Ceftiofur 0.0 0.8 [0.0 - 4.6] 0.8 22.0 73.7 2.5 0.8
Ceftriaxone 0.0 0.8 [0.0 - 4.6] 99.2 0.8
Macrolide Azithromycin N/A 0.0 [0.0 - 3.1] 6.8 89.0 4.2
Penicillins Ampicillin 0.0 28.8 [20.8 - 37.9] 69.5 1.7 28.8
Quinolones Ciprofloxacin 0.8 0.0 [0.0 - 3.1] 98.3 0.8 0.8
Nalidixic acid N/A 0.8 [0.0 - 4.6] 0.8 49.2 48.3 0.8 0.8
Cephems Cefoxitin 0.0 0.8 [0.0 - 4.6] 27.1 63.6 8.5 0.8
Folate pathway inhibitors Sulfisoxazole N/A 28.8 [20.8 - 37.9] 3.4 47.5 19.5 0.8 28.8
Trimethoprim-sulfamethoxazole N/A 0.0 [0.0 - 3.1] 100.0
Phenicols Chloramphenicol 0.8 0.0 [0.0 - 3.1] 0.8 55.1 43.2 0.8









Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
























Antimicrobial Agent Susceptible, Intermediate, and Resistant Proportion 
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Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
































































































































































































































































































































At least ACSSuT† 





Resistance ≥ 1 CLSI class*
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*




No resistance detected 
At least ceftriaxone and nalidixic acid 
resistant
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 




2. Typhoidal Salmonella 
 
A. Salmonella ser. Typhi 
 
Table 27.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Typhi isolates to 
antimicrobial agents, 2012 (N=326)
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.0 [0.0 - 1.1] 50.3 47.9 1.8
Kanamycin 0.0 0.0 [0.0 - 1.1] 100.0
Streptomycin N/A 9.2 [6.3 - 12.9] 90.8 9.2
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.6 0.0 [0.0 - 1.1] 89.0 0.6 1.5 8.3 0.6
Cephems Ceftiofur 0.0 0.0 [0.0 - 1.1] 0.6 3.4 75.5 20.2 0.3
Ceftriaxone 0.0 0.0 [0.0 - 1.1] 100.0
Macrolide Azithromycin N/A 0.0 [0.0 - 1.1] 1.8 25.8 68.1 4.3
Penicillins Ampicillin 0.0 10.1 [7.1 - 13.9] 88.7 0.9 0.3 10.1
Quinolones Ciprofloxacin 62.0 6.4 [4.0 - 9.7] 30.1 0.3 1.2 9.8 38.7 13.5 0.6 0.3 5.5
Nalidixic acid N/A 68.4 [63.1 - 73.4] 0.9 3.1 25.5 1.2 0.9 1.5 66.9
Cephems Cefoxitin 0.3 0.0 [0.0 - 1.1] 3.1 23.0 16.0 44.5 13.2 0.3
Folate pathway inhibitors Sulfisoxazole N/A 10.4 [7.3 - 14.3] 45.7 37.7 5.2 0.6 0.3 10.4
Trimethoprim-sulfamethoxazole N/A 10.1 [7.1 - 13.9] 89.0 0.3 0.6 10.1
Phenicols Chloramphenicol 0.3 10.1 [7.1 - 13.9] 2.1 70.9 16.6 0.3 10.1









Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
























Antimicrobial Agent Susceptible, Intermediate, and Resistant Proportion 
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Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 




































































































































































































































































































































No resistance detected 
Resistance ≥ 1 CLSI class*
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least ACSSuT† 




At least ceftriaxone and nalidixic acid 
resistant
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 




B. Salmonella  ser. Paratyphi A, Paratyphi B (tartrate negative), and Paratyphi C 
 
Table 30.  Frequency of Salmonella ser. Paratyphi A, Paratyphi B (tartrate negative), and Paratyphi C, 2012 
(see Methods for varying sampling method by serotype) 
n (%)
Paratyphi A 111 (99.1)
Paratyphi B 1 (0.9)





Table 31.  Minimum inhibitory concentrations (MICs) and resistance of Salmonella ser. Paratyphi A 
isolates to antimicrobial agents, 2012 (N=111) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.0 [0.0 - 3.3] 98.2 1.8
Kanamycin 0.0 0.0 [0.0 - 3.3] 100.0
Streptomycin N/A 0.0 [0.0 - 3.3] 100.0
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.0 0.0 [0.0 - 3.3] 49.5 46.8 3.6
Cephems Ceftiofur 0.0 0.0 [0.0 - 3.3] 0.9 4.5 94.6
Ceftriaxone 0.0 0.0 [0.0 - 3.3] 100.0
Macrolide Azithromycin N/A 0.0 [0.0 - 3.3] 1.8 38.7 55.9 3.6
Penicillins Ampicillin 0.0 0.0 [0.0 - 3.3] 7.2 87.4 5.4
Quinolones Ciprofloxacin 92.8 2.7 [0.5 - 7.7] 4.5 0.9 1.8 90.1 2.7
Nalidixic acid N/A 94.6 [88.6 - 98.0] 1.8 2.7 0.9 94.6
Cephems Cefoxitin 0.0 0.0 [0.0 - 3.3] 4.5 72.1 23.4
Folate pathway inhibitors Sulfisoxazole N/A 0.0 [0.0 - 3.3] 6.3 82.9 10.8
Trimethoprim-sulfamethoxazole N/A 0.0 [0.0 - 3.3] 93.7 6.3
Phenicols Chloramphenicol 9.0 0.9 [0.0 - 4.9] 2.7 87.4 9.0 0.9









Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
  
 




















Antimicrobial Agent Susceptible, Intermediate, and Resistant Proportion 
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Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 




































































































































































































































































































































No resistance detected 
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least ACSSuT† 
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ASSuT: resistance to ampicillin, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole
ACSSuTAuCx: resistance to ACSSuT, amoxicillin-clavulanic acid, ceftriaxone 
AAuCx: resistance to ampicillin, amoxicillin-clavulanic acid, ceftriaxone













Table 34.  Frequency of Shigella species, 2012 
n (%)
Shigella sonnei 287 (81.3)
Shigella flexneri 59 (16.7)






Table 35.  Minimum inhibitory concentrations (MICs) and resistance of Shigella isolates to antimicrobial 
agents, 2012 (N=353)
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.0 [0.0 - 1.0] 2.3 14.7 78.5 4.5
Kanamycin 0.0 0.3 [0.0 - 1.6] 99.7 0.3
Streptomycin N/A 83.0 [78.7 - 86.8] 17.0 43.1 39.9
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 14.2 1.7 [0.6 - 3.7] 5.9 6.2 56.9 15.0 14.2 1.1 0.6
Cephems Ceftiofur 0.0 1.1 [0.3 - 2.9] 10.2 70.5 13.0 5.1 0.3 0.8
Ceftriaxone 0.0 1.1 [0.3 - 2.9] 98.3 0.6 0.3 0.3 0.6
Macrolide Azithromycin N/A 4.2 [2.4 - 6.9] 0.3 2.0 6.5 9.3 72.5 4.5 0.6 4.2
Penicillins Ampicillin 0.3 25.5 [21.0 - 30.4] 9.6 53.0 11.6 0.3 0.3 25.2
Quinolones Ciprofloxacin 0.0 2.0 [0.8 - 4.0] 93.5 0.8 0.6 1.4 0.6 0.8 0.3 0.8 1.1
Nalidixic acid N/A 4.5 [2.6 - 7.3] 0.6 74.8 17.0 3.1 0.6 4.0
Cephems Cefoxitin 0.6 0.6 [0.1 - 2.0] 5.7 69.7 22.4 1.1 0.6 0.6
Folate pathway inhibitors Sulfisoxazole N/A 34.8 [29.9 - 40.1] 51.6 9.3 4.0 0.3 34.8
Trimethoprim-sulfamethoxazole N/A 43.3 [38.1 - 48.7] 12.2 2.3 3.7 19.5 19.0 7.9 35.4
Phenicols Chloramphenicol 0.0 11.3 [8.2 - 15.1] 12.7 69.4 6.5 2.0 9.3









Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 




















Antimicrobial Agent Susceptible, Intermediate, and Resistant Proportion 
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Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 



































































































































































































































































































































No resistance detected 
Resistance ≥ 1 CLSI class*
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*





At least ceftriaxone and nalidixic acid 
resistant
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute 
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
AT/S: resistance to ampicillin, trimethoprim-sulfamethoxazole
ANT/S: resistance to AT/S, nalidixic acid




Table 38.  Minimum inhibitory concentrations (MICs) and resistance of Shigella sonnei isolates to 
antimicrobial agents, 2012 (N=287)
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.0 [0.0 - 1.3] 2.1 12.9 79.8 5.2
Kanamycin 0.0 0.3 [0.0 - 1.9] 99.7 0.3
Streptomycin N/A 89.2 [85.0 - 92.5] 10.8 49.8 39.4
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 6.6 1.7 [0.6 - 4.0] 4.9 2.4 67.9 16.4 6.6 1.0 0.7
Cephems Ceftiofur 0.0 1.0 [0.2 - 3.0] 4.5 76.3 12.5 5.6 0.3 0.7
Ceftriaxone 0.0 1.0 [0.2 - 3.0] 98.3 0.7 0.3 0.7
Macrolide Azithromycin N/A 2.1 [0.8 - 4.5] 0.3 1.4 3.8 86.8 5.2 0.3 2.1
Penicillins Ampicillin 0.3 18.1 [13.8 - 23.1] 4.9 63.1 13.6 0.3 0.3 17.8
Quinolones Ciprofloxacin 0.0 2.1 [0.8 - 4.5] 94.4 0.3 0.3 1.0 0.7 0.7 0.3 1.0 1.0
Nalidixic acid N/A 4.2 [2.2 - 7.2] 0.7 77.7 14.6 2.8 0.3 3.8
Cephems Cefoxitin 0.7 0.7 [0.1 - 2.5] 6.6 78.4 13.6 0.7 0.7
Folate pathway inhibitors Sulfisoxazole N/A 30.0 [24.7 - 35.6] 55.1 10.5 4.5 30.0
Trimethoprim-sulfamethoxazole N/A 41.8 [36.0 - 47.8] 6.3 1.4 3.5 24.0 23.0 9.8 32.1
Phenicols Chloramphenicol 0.0 3.1 [1.4 - 5.9] 5.6 83.3 8.0 3.1









Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 




















Antimicrobial Agent Susceptible, Intermediate, and Resistant Proportion 
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Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 


































































































































































































































































































































No resistance detected 
Resistance ≥ 1 CLSI class*
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*





At least ceftriaxone and nalidixic acid 
resistant
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute 
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
AT/S: resistance to ampicillin, trimethoprim-sulfamethoxazole
ANT/S: resistance to AT/S, nalidixic acid





Table 41.  Minimum inhibitory concentrations and resistance of Shigella flexneri isolates to antimicrobial 
agents, 2012 (N=59)
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.0 [0.0 - 6.1] 1.7 22.0 74.6 1.7
Kanamycin 0.0 0.0 [0.0 - 6.1] 100.0
Streptomycin N/A 55.9 [42.4 - 68.8] 44.1 15.3 40.7
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 52.5 1.7 [0.0 - 9.1] 6.8 25.4 5.1 8.5 52.5 1.7
Cephems Ceftiofur 0.0 1.7 [0.0 - 9.1] 32.2 47.5 16.9 1.7 1.7
Ceftriaxone 0.0 1.7 [0.0 - 9.1] 98.3 1.7
Macrolide Azithromycin N/A 15.3 [7.2 - 27.0] 11.9 25.4 33.9 10.2 1.7 1.7 15.3
Penicillins Ampicillin 0.0 61.0 [47.4 - 73.5] 28.8 6.8 3.4 61.0
Quinolones Ciprofloxacin 0.0 1.7 [0.0 - 9.1] 93.2 1.7 1.7 1.7 1.7
Nalidixic acid N/A 5.1 [1.0 - 14.1] 64.4 27.1 3.4 5.1
Cephems Cefoxitin 0.0 0.0 [0.0 - 6.1] 1.7 25.4 66.1 6.8
Folate pathway inhibitors Sulfisoxazole N/A 55.9 [42.4 - 68.8] 37.3 3.4 1.7 1.7 55.9
Trimethoprim-sulfamethoxazole N/A 50.8 [37.5 - 64.1] 37.3 5.1 5.1 1.7 50.8
Phenicols Chloramphenicol 0.0 52.5 [39.1 - 65.7] 39.0 8.5 11.9 40.7









Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates with MIC (µg/mL)**
 
 




















Antimicrobial Agent Susceptible, Intermediate, and Resistant Proportion 
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Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly 
Important
CLSI: Clinical and Laboratory Standards Institute 


































































































































































































































































































































No resistance detected 
Resistance ≥ 1 CLSI class*
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*





At least ceftriaxone and nalidixic acid 
resistant
At least nalidixic acid and azithromycin 
resistant
At least ceftriaxone and azithromycin 
resistant
CLSI: Clinical and Laboratory Standards Institute 
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
AT/S: resistance to ampicillin, trimethoprim-sulfamethoxazole
ANT/S: resistance to AT/S, nalidixic acid




4. Escherichia coli O157 
 
Table 44.  Minimum inhibitory concentrations (MICs) and resistance of Escherichia coli O157 isolates to 
antimicrobial agents, 2012 (N=166) 
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin 0.0 0.6 [0.0 - 3.3] 7.8 78.3 13.3 0.6
Kanamycin 0.0 0.0 [0.0 - 2.2] 100.0
Streptomycin N/A 2.4 [0.7 - 6.1] 97.6 0.6 1.8
β-lactam / β-lactamase 
inhibitor combinations
Amoxicillin-clavulanic acid 0.0 0.6 [0.0 - 3.3] 3.0 6.0 88.6 1.8 0.6
Cephems Ceftiofur 0.0 0.6 [0.0 - 3.3] 1.2 6.0 90.4 1.8 0.6
Ceftriaxone 0.0 0.6 [0.0 - 3.3] 99.4 0.6
Macrolide Azithromycin N/A 0.6 [0.0 - 3.3] 0.6 7.8 77.1 13.9 0.6
Penicillins Ampicillin 0.0 1.8 [0.4 - 5.2] 5.4 77.7 15.1 1.8
Quinolones Ciprofloxacin 0.0 0.0 [0.0 - 2.2] 95.8 1.8 1.8 0.6
Nalidixic acid N/A 2.4 [0.7 - 6.1] 0.6 1.2 81.9 13.3 0.6 2.4
Cephems Cefoxitin 1.2 0.6 [0.0 - 3.3] 1.2 6.0 73.5 17.5 1.2 0.6
Folate pathway inhibitors Sulf isoxazole N/A 3.6 [1.3 - 7.7] 77.7 15.7 3.0 3.6
Trimethoprim-sulfamethoxazole N/A 1.2 [0.1 - 4.3] 98.2 0.6 1.2
Phenicols Chloramphenicol 1.2 1.8 [0.4 - 5.2] 0.6 15.1 81.3 1.2 0.6 1.2









Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if  no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method 
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to 
or less than the low est tested concentration. CLSI breakpoints w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
Percentage of isolates Percentage of all isolates w ith MIC (µg/mL)**
 
 




















Antimicrobial Agent Susceptible, Intermediate, and Resistant Proportion 
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Rank of antimicrobials is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 











































































































































































































































At least ceftriaxone and nalidixic acid 
resistant
CLSI: Clinical and Laboratory Standards Institute
ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
ACT/S: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole




No resistance detected 
Resistance ≥ 1 CLSI class*
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*









Table 47.  Frequency of Campylobacter species, 2012 
n (%)
Campylobacter jejuni 1191 (86.3)







Table 48.  Minimum inhibitory concentrations (MICs) and resistance of Campylobacter jejuni isolates to 
antimicrobial agents, 2012 (N=1191)
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin N/A 1.0 [0.5 - 1.8] 3.0 27.0 57.4 11.4 0.2 0.1 0.3 0.7
Ketolide Telithromycin N/A 1.4 [0.8 - 2.3] 0.1 0.3 3.3 19.1 38.8 31.0 6.0 0.3 1.1
Macrolides Azithromycin N/A 1.8 [1.1 - 2.7] 0.7 9.6 32.8 34.3 20.9 0.3 0.1 0.3 1.2
Erythromycin N/A 1.5 [0.9 - 2.4] 0.1 1.6 19.5 26.1 35.3 14.4 1.5 0.1 0.3 1.2
Quinolones Ciprofloxacin N/A 25.3 [22.8 - 27.8] 0.2 0.6 22.8 42.1 8.2 0.8 0.3 0.1 1.7 9.1 8.1 3.4 1.6 1.1
Nalidixic acid N/A 25.5 [23.1 - 28.1] 56.7 16.6 1.2 2.0 23.5
Lincosamides Clindamycin N/A 10.8 [9.1 - 12.7] 0.7 8.9 30.1 23.3 26.2 8.4 0.8 0.2 0.3 0.3 0.8
Phenicols Florfenicol N/A 1.4 [0.8 - 2.3] 2.9 53.7 34.4 7.5 1.0 0.3 0.2









Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages 
of isolates w ith MICs equal to or less than the low est tested concentration. ECOFFs w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent


















Antimicrobial Agent Susceptible, Intermediate, and Resistant Proportion 
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Resistance ≥ 1 CLSI class*
Resistance ≥ 2 CLSI classes*
Resistance Pattern
No resistance detected 
At least quinolone and macrolide resistant
CLSI: Clinical and Laboratory Standards Institute
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*






Table 51.  Minimum inhibitory concentrations (MICs) and resistance of Campylobacter coli isolates to 
antimicrobial agents, 2012 (N=134)
%I‡ %R§ [95% CI]¶ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin N/A 6.0 [2.6 - 11.4] 25.4 38.1 29.1 1.5 1.5 4.5
Ketolide Telithromycin N/A 11.2 [6.4 - 17.8] 0.7 1.5 12.7 25.4 4.5 17.2 26.9 4.5 6.7
Macrolides Azithromycin N/A 9.0 [4.7 - 15.1] 1.5 16.4 36.6 25.4 11.2 1.5 7.5
Erythromycin N/A 9.0 [4.7 - 15.1] 0.7 5.2 27.6 21.6 19.4 14.9 1.5 1.5 7.5
Quinolones Ciprofloxacin N/A 33.6 [25.7 - 42.2] 0.7 1.5 9.0 29.9 20.1 5.2 2.2 5.2 11.2 13.4 1.5
Nalidixic acid N/A 33.6 [25.7 - 42.2] 23.1 40.3 3.0 4.5 29.1
Lincosamides Clindamycin N/A 16.4 [10.6 - 23.8] 0.7 6.7 34.3 24.6 17.2 6.7 0.7 0.7 5.2 3.0
Phenicols Florfenicol N/A 1.5 [0.2 - 5.3] 3.7 35.8 42.5 16.4 0.7 0.7









Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists
Percentage of isolates that w ere resistant
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method
The unshaded areas indicate the dilution range of the Sensititre® plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the 
shaded areas indicate the percentages of isolates w ith MICs greater than the highest concentrations on the Sensititre® plate. Numbers listed for the low est tested concentrations represent the percentages 
of isolates w ith MICs equal to or less than the low est tested concentration. ECOFFs w ere used w hen available.
Rank* CLSI† Antimicrobial Class Antimicrobial Agent
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No resistance detected 
Resistance ≥ 2 CLSI classes*
Resistance ≥ 3 CLSI classes*
Resistance ≥ 4 CLSI classes*
Resistance ≥ 5 CLSI classes*
At least quinolone and macrolide resistant





6. Vibrio species other than V. cholerae 
 
Table 54.  Frequency of Vibrio species other than V. cholerae, 2009–2012 
n (%) n (%) n (%) n (%)
Vibrio parahaemolyticus 149 (52.8) 179 (54.2) 201 (50.3) 370 (61.4)
Vibrio alginolyticus 46 (16.3) 49 (14.8) 103 (25.8) 117 (19.4)
Vibrio vulnificus 50 (17.7) 61 (18.5) 63 (15.8) 65 (10.8)
Vibrio fluvialis 21 (7.4) 24 (7.3) 18 (4.5) 28 (4.6)
Vibrio mimicus 11 (3.9) 9 (2.7) 9 (2.3) 11 (1.8)
Vibrio harveyi 0 (0) 2 (0.6) 4 (1.0) 3 (0.5)
Other 5 (1.8) 6 (1.8) 2 (0.5) 9 (1.5)
Total 282 (100) 330 (100) 400 (100) 603 (100)
Species 2009 2010 2011 2012
 
 
Table 55.  Minimum inhibitory concentrations (MICs) and resistance of isolates of Vibrio species other 
than V. cholerae to antimicrobial agents, 2012 (N=603) 
CLSI† Antimicrobial Class
   Antimicrobial Agent Species  (# of isolates) %I‡ %R§ [95% CI]¶ 0.002 0.004 0.007 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Aminoglycosides
   Kanamycin†† All (603) N/A N/A N/A 2.5 49.3 42.3 5.6 0.3
parahaemolyticus  (370) N/A N/A N/A 1.6 50.0 47.0 1.4
alginolyticus  (117) N/A N/A N/A 1.7 64.1 33.3 0.9
vulnificus  (65) N/A N/A N/A 6.2 50.8 40.0 3.1
   Streptomycin†† All (603) N/A N/A N/A 0.2 1.8 5.8 50.1 40.8 1.0 0.2 0.2
parahaemolyticus  (370) N/A N/A N/A 0.5 1.1 50.5 46.8 0.5 0.3 0.3
alginolyticus  (117) N/A N/A N/A 0.9 7.7 82.9 8.5
vulnificus  (65) N/A N/A N/A 3.1 6.2 86.2 4.6
Penicillins
   Ampicillin All (603) 15.8 29.9 [26.2 - 33.7] 0.3 10.0 10.3 20.2 13.6 15.8 8.5 2.8 1.7 2.5 14.4
parahaemolyticus  (370) 23.2 14.1 [10.7 - 18.0] 0.8 13.8 28.1 20.0 23.2 9.7 2.7 0.3 1.4
alginolyticus  (117) 0.9 98.3 [94.0 - 99.8] 0.9 0.9 6.0 6.0 6.8 10.3 69.2
vulnificus  (65) 0.0 1.5 [0.0 - 8.3] 1.5 84.6 9.2 3.1 1.5
Quinolones
   Ciprofloxacin All (603) 0.0 0.0 [0.0 - 0.6] 0.2 0.8 4.5 0.7 6.3 12.4 46.8 26.9 1.5
parahaemolyticus  (370) 0.0 0.0 [0.0 - 1.0] 0.3 0.5 0.3 3.0 5.4 61.9 28.4 0.3
alginolyticus  (117) 0.0 0.0 [0.0 - 3.1] 3.4 8.5 40.2 45.3 2.6
vulnificus  (65) 0.0 0.0 [0.0 - 5.5] 1.5 1.5 32.3 61.5 3.1
   Nalidixic acid†† All (603) N/A N/A N/A 0.5 3.2 25.0 60.9 9.3 0.8 0.2 0.2
parahaemolyticus  (370) N/A N/A N/A 2.2 21.9 67.0 7.6 1.1 0.3
alginolyticus  (117) N/A N/A N/A 0.9 2.6 25.6 58.1 12.0 0.9
vulnificus  (65) N/A N/A N/A 1.5 3.1 30.8 47.7 16.9
Cephems
   Cephalothin†† All (603) N/A N/A N/A 0.3 1.8 4.8 31.2 52.2 5.8 0.2 0.2 0.2 3.3
parahaemolyticus  (370) N/A N/A N/A 3.0 24.9 64.1 7.3 0.3 0.3 0.3
alginolyticus  (117) N/A N/A N/A 0.9 0.9 0.9 34.2 59.0 4.3
vulnificus  (65) N/A N/A N/A 10.8 81.5 6.2 1.5
Folate pathway inhibitors
   Trimethoprim-sulfamethoxazole All (603) N/A 0.0 [0.0 - 0.6] 0.2 0.3 4.0 49.3 44.4 1.8
parahaemolyticus  (370) N/A 0.0 [0.0 - 1.0] 0.3 0.5 28.4 68.1 2.7
alginolyticus  (117) N/A 0.0 [0.0 - 3.1] 0.9 0.9 88.9 9.4
vulnificus  (65) N/A 0.0 [0.0 - 5.5] 1.5 24.6 70.8 1.5 1.5
Phenicols
   Chloramphenicol†† All (603) N/A N/A N/A 0.2 1.8 75.6 21.2 0.5 0.3 0.3
parahaemolyticus  (370) N/A N/A N/A 68.6 29.7 0.8 0.3 0.5
alginolyticus  (117) N/A N/A N/A 0.9 3.4 88.0 7.7
vulnificus  (65) N/A N/A N/A 7.7 90.8 1.5
Tetracyclines
   Tetracycline All (603) 0.3 0.3 [0.0 - 1.2] 0.2 0.5 3.3 36.3 52.6 6.5 0.3 0.2 0.2
parahaemolyticus  (370) 0.5 0.5 [0.1 - 1.9] 0.3 28.6 63.8 6.2 0.5 0.3 0.3
alginolyticus  (117) 0.0 0.0 [0.0 - 3.1] 2.6 51.3 45.3 0.9








Rank of antimicrobial agents is based on World Health Organization's categorization of critical importance in human medicine (Appendix B, Table 1):  Rank I, Critically Important; Rank II, Highly Important
CLSI: Clinical and Laboratory Standards Institute 
Percentage of isolates w ith intermediate susceptibility; N/A if no MIC range of intermediate susceptibility exists or no CLSI breakpoints have been established
Percentage of isolates that w ere resistant; N/A indicates that no CLSI breakpoints have been established
The 95% confidence intervals (CI) for percent resistant (%R) w ere calculated using the Paulson-Camp-Pratt approximation to the Clopper-Pearson exact method; N/A indicates that no CLSI breakpoints have been established
The unshaded areas indicate the dilution range of the Etest® strips used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, w hile double vertical bars indicate breakpoints for resistance. Numbers in the shaded areas indicate the 
percentages of isolates w ith MICs greater than the highest concentrations on the Etest® strip. Numbers listed for the low est tested concentrations represent the percentages of isolates w ith MICs equal to or less than the low est tested concentration. CLSI 
breakpoints w ere used w hen available.
CLSI MIC interpretive criteria have not been established
Rank*








Table 56.  Percentage and number of isolates of Vibrio species other than V. cholerae resistant to 
ampicillin, 2009–2012 















































































The following figures display resistance to selected agents and combinations of agents from 1996–2012 for non-
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Figure 21.  Percentage of Salmonella ser. Typhimurium isolates resistant to at least ampicillin, 
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Figure 22.  Percentage of Salmonella ser. Newport isolates resistant to at least ampicillin, 
chloramphenicol, streptomycin, sulfonamide, tetracycline, amoxicillin-clavulanic acid, and ceftriaxone 




Figure 23.  Percentage of non-typhoidal Salmonella isolates resistant to 1 or more antimicrobial classes, 
by year, 1996–2012 
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Figure 24.  Percentage of non-typhoidal Salmonella isolates resistant to 3 or more antimicrobial classes, 








 Upper and lower limits of the individual 95% confidence intervals for annual percent resistant  
Annual percent resistant 
 
 
Upper and lower limits of the individual 95% confidence intervals for annual percentage resistant 
Annual percentage resistant 
 
 Upper and lower limits of the individual 95% confidence intervals for annual percent resistant  
Annual percent resistant 
 
 
Upper and lower limits of the individual 95% confidence intervals for annual percentage resistant 
Annual percentage resistant 
 
80 
Figure 26.  Percentage of Campylobacter jejuni isolates resistant to ciprofloxacin, by year, 1997–2012 
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Figure 28.  Percentage of Shigella isolates resistant to nalidixic acid, by year, 1999–2012 
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In 2011 the World Health Organization (WHO) convened a panel of experts to update a list of antimicrobial agents 
ranked according to their relative importance to human medicine (WHO, 2011).  The participants categorized 
antimicrobial agents as either Critically Important, Highly Important, or Important based upon two criteria: (1) used 
as sole therapy or one of the few alternatives to treat serious human disease and (2) used to treat disease caused 
by either organisms that may be transmitted via non–human sources or diseases caused by organisms that may 
acquire resistance genes from non–human sources  Antimicrobial agents tested in NARMS have been included in 
the WHO categorization table. 
 
 Antimicrobial agents are critically important if both criteria (1) and (2) are true. 
 Antimicrobial agents are highly important if either criterion (1) or (2) is true. 
 Antimicrobial agents are important if neither criterion is true. 
 




Importance CLSI* Class 
Antimicrobial Agent tested in 
NARMS 

























    




Folate pathway inhibitors 






* CLSI: Clinical and Laboratory Standards Institute 




Appendix B.  Criteria for Retesting of Isolates 
Repeat testing of an isolate must be done when one or more of the following conditions occur: 
 No growth on panel 
 Growth in all wells  
 Multiple skip patterns  
 Apparent contamination in wells or isolate preparation 
 Unlikely or discordant susceptibility results (Table B1) 
If an isolate is retested, data for all antimicrobial agents should be replaced with the new test results. Categorical 
changes may require a third test (and may indicate a mixed culture). Uncommon test results (Table B2) may 
represent emerging resistance phenotypes.  Retesting is encouraged.   
 
Table B1.  Retest criteria for unlikely or discordant resistance phenotypes 
Organism(s) Resistance phenotype (MIC values in µg/mL) Comments 
Salmonella /   E. 












The presence of an ESBL
*
 or AmpC beta-
lactamase should confer resistance to ampicillin 
ceftiofur
R





 (≤2) AND ceftriaxone
R 
(≥4)  
Both antimicrobial agents are 3
rd
 generation β-









Salmonella and  
E. coli O157 
sulfisoxazole
S





Salmonella  nalidixic acid
S




The stepwise selection of mutations in the QRDR
† 
 
does not support this phenotype, although it may 
occur with plasmid-mediated mechanisms 








The stepwise selection of mutations in the QRDR
†
 
does not support this phenotype 
Campylobacter 
jejuni and coli 
nalidixic acid
S
 (≤16) AND  
ciprofloxacin
R
 (≥1) In Campylobacter, one mutation is sufficient to 
confer resistance to both nalidixic acid and 
ciprofloxacin nalidixic acid
R








 (≤4) AND  
azithromycin
R
 (≥0.5)  
Erythromycin is class representative for 14- and 
15-membered macrolides (azithromycin, 
clarithromycin, roxithromycin, and dirithromycin) 
erythromycin
R 



















* Extended-spectrum beta-lactamase 
† Quinolone resistance-determining regions 
 
Table B2.  Uncommon resistance phenotypes for which retesting is encouraged 
Organism(s) Resistance phenotype (MIC values in µg/mL) 
Salmonella /   E. 
coli O157 / 
Shigella 
Pan-resistance  
Resistance to azithromycin (>16) 
ceftriaxone and/or ceftiofur MIC ≥2 AND  
ciprofloxacin MIC ≥0.125 and/or nalidixic acid MIC ≥32 
Campylobacter 
jejuni and coli 
Pan-resistance  
Resistance to gentamicin (≥4)  
Resistance to florfenicol (≥8) 
Vibrio Resistance to ciprofloxacin (>2) 
Resistance to tetracycline (>8) 
Resistance to trimethoprim-sulfamethoxazole (>2) 
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